



US 20120328629A1

(19) **United States**

(12) **Patent Application Publication**
Freeman et al.

(10) **Pub. No.: US 2012/0328629 A1**

(43) **Pub. Date: Dec. 27, 2012**

(54) **THERAPEUTIC APPLICATIONS TARGETING SARM1**

Publication Classification

(75) Inventors: **Marc Freeman**, Barre, MA (US);
Stephan Zuchner, Pinecrest, FL (US)

(73) Assignees: **UNIVERSITY OF MIAMI**, Miami, FL (US); **UNIVERSITY OF MASSACHUSETTS**, Shrewsbury, MA (US)

(21) Appl. No.: **13/530,998**

(22) Filed: **Jun. 22, 2012**

Related U.S. Application Data

(60) Provisional application No. 61/501,111, filed on Jun. 24, 2011.

(51) **Int. Cl.**

<i>A61K 39/395</i>	(2006.01)
<i>A61K 31/7088</i>	(2006.01)
<i>A61K 31/713</i>	(2006.01)
<i>A61P 25/00</i>	(2006.01)
<i>A61K 38/02</i>	(2006.01)
<i>C40B 30/04</i>	(2006.01)
<i>G01N 33/53</i>	(2006.01)
<i>C12N 5/0793</i>	(2010.01)
<i>A61K 31/712</i>	(2006.01)

(52) **U.S. Cl.** **424/172.1**; 435/375; 514/44 A; 514/17.7; 506/9; 435/7.1; 436/501

(57) **ABSTRACT**

The present disclosure provides methods for reducing axonal and/or synaptic degradation in neurons by modulating sterile α /Armadillo/Toll-Interleukin receptor homology domain protein (SARM) activity and/or expression.





FIG. 1A



FIGs. 1B-E




FIG. 1F




FIG. 1G




FIG. 1H




FIG. 11




FIG. 2A

mutant line	genomic location of lesion	original nucleotide	new nucleotide	resulting protein change
<i>I(3)896</i>	8,096,399	C	T	Q603Stop
<i>I(3)4621</i>	8,092,275	C	A	D347E
<i>I(3)4621</i>	8,097,436	G	A	W949Stop
<i>I(3)4705</i>	8,096,632	C	T	Q681Stop

FIG. 2B




FIG. 2C








FIG. 2D



FIGs. 3A-B



FIGs. 3C-H



FIGs. 4A-B




FIG. 4C




FIG. 4D

FIG. 4E







FIG. 4F






FIG. 6A




FIG. 6B

THERAPEUTIC APPLICATIONS TARGETING SARM1

CLAIM OF PRIORITY

[0001] This application claims the benefit of U.S. Provisional Patent Application Ser. No. 61/501,111, filed on Jun. 24, 2011, the entire contents of which are hereby incorporated by reference.

FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT

[0002] This invention was made with Government support under Grant Nos. R01 NS059991, U54NS065712, and R01NS072248, awarded by the National Institutes of Health. The Government has certain rights in the invention.

TECHNICAL FIELD

[0003] The present disclosure relates to compositions and methods for modulating sterile α /Armadillo/Toll-Interleukin receptor homology domain protein (SARM1) for use in the treatment of neurological disorders that manifest and/or include axonal and/or synaptic degradation (e.g., neurodegenerative disorders).

BACKGROUND

[0004] Widespread axonal and synaptic degeneration is a hallmark of peripheral neuropathy, brain injury, and neurodegenerative disease. Neurodegeneration and neurodegenerative disorders include progressive structural and/or functional loss of nerve cells or neurons in the peripheral nervous system (PNS) and/or central nervous system (CNS). Axon degeneration has been proposed to be mediated by an active auto-destruction program, akin to apoptotic cell death, however loss of function mutations capable of potentially blocking axon self-destruction have not been described.

[0005] Axons have traditionally been thought to be strictly dependent upon the cell body for survival, as axons robustly degenerate upon separation from the soma (Waller, *Philos. Trans. R. Soc. Lond. B Biol. Sci.* 140, 423 (1850)). However, this notion was directly challenged by the identification of the slow Wallerian degeneration (Wld^S) mutant mouse in which the distal portion of severed axons remained morphologically intact for 2-3 weeks after axotomy (Lunn et al., *Eur J Neurosci* 1, 27 (1989); Glass et al., *J Neurocytol* 22, 311 (1993)). The remarkable long-term survival of severed axons in the Wld^S mouse also raised the intriguing possibility that Wallerian degeneration is driven by an active molecular program akin to apoptotic cell death signaling (Raff et al., *Science* 296, 868 (2002); Coleman and Perry, *Trends Neurosci* 25, 532 (2002)). However numerous studies have demonstrated that Wld^S is a gain-of-function mutation that results in the neuronal overexpression of a chimeric fusion protein containing the NAD⁺ biosynthetic enzyme *Nmnat1* (Mack et al., *Nat Neurosci* 4, 1199 (2001); Coleman and Freeman, *Annu Rev Neurosci* 33, 245 (2010)). As such, the Wld^S phenotype may be unrelated to normal *Nmnat1* function and NAD⁺ metabolism, despite its ability to inhibit endogenous axon death pathways. Wallerian degeneration appears to be molecularly distinct from apoptosis since potent genetic or chemical inhibitors of cell death (Deckwerth and Johnson, Jr., *Dev Biol* 165, 63 (1994); Finn et al., *J Neurosci* 20, 1333 (2000); Whitmore et al., *Cell Death Differ* 10, 260 (2003)) or the ubiquitin proteasome pathway (Zhai et al., *Neuron* 39, 217

(2003); Hoopfer et al., *Neuron* 50, 883 (2006)) do not block Wallerian degeneration. Mutants reported to affect Wallerian degeneration, such as *wnd/DLK*, delay the clearance of degenerating axons in *Drosophila* for only ~1-2 days, and mouse axons for several hours (Miller et al., *Nat Neurosci* 12, 387 (2009))—an extremely weak degree of suppression when compared to Wld^S . Thus the existence of axon death pathways has remained only speculative. Compositions and methods for treating neurodegeneration and neurodegenerative disorders in the PNS and CNS are needed.

SUMMARY

[0006] The present disclosure provides compositions and methods related to the modulation (e.g., inhibition) of SARM expression and/or activity for the treatment of neurodegeneration that manifests and/or includes axonal and/or synaptic degradation in a subject.

[0007] In some aspects, the disclosure provides methods for reducing axonal and/or synaptic degradation in a neuron. Such methods can include selecting, providing, or obtaining a neuron with, undergoing, or at risk for axonal and/or synaptic degradation, and contacting or treating the neuron with an effective amount of a composition that inhibits sterile α /Armadillo/Toll-Interleukin receptor homology domain protein (SARM) activity and/or expression for a time sufficient to inhibit SARM activity and/or expression, thereby reducing axonal and/or synaptic degradation in the neuron. In some embodiments, these methods are performed in vitro. In other embodiments, the methods are performed in vivo.

[0008] In other aspects, the disclosure provides methods for reducing axonal and/or synaptic degradation in a subject with or at risk for developing axonal and/or synaptic degradation, for example, in the central and/or peripheral nervous system. Such methods can include selecting a subject with or at risk for developing axonal and/or synaptic degradation, and treating the subject with, or administering to the subject, an effective amount or dose of a composition that inhibits SARM activity and/or expression, thereby reducing axonal and/or synaptic degradation in the subject. In some embodiments, subjects suitable for treatment can have or be at risk of developing neurodegenerative disease. In addition, such subjects can have or be at risk of developing axonal and/or synaptic degradation in the central and/or peripheral nervous system. In some embodiments, a subject with or at risk of developing axonal and/or synaptic degradation can have diabetes and/or diabetic neuropathy (e.g., peripheral neuropathy). Alternatively or in addition, the subject can be scheduled to receive chemotherapy, undergoing chemotherapy, and/or have previously had chemotherapy.

[0009] In further aspects, the disclosure includes methods for identifying compounds that inhibit SARM activity and/or expression. Such methods can include providing or obtaining a sample containing SARM, contacting the sample or SARM with a compound (e.g., a test compound), and determining whether the test compound interacts with or binds to SARM, wherein a compound that interacts or binds with SARM is a candidate compound that inhibits SARM activity and/or expression. In some embodiments, such methods are performed entirely or partially in silico or bioinformatically, e.g., via modeling. In other instances, the methods are performed in vitro. For example, SARM (e.g., isolated SARM, portions or SARM, or isolated SARM domains) are physically contacted with the test compound. Either way, the methods can include determining whether the compound interacts with or

binds to SARM directly, e.g., by assessing the interaction of SARM and the compound in the absence of other components. Alternatively or in addition, the methods can include determining whether the compound interacts with or binds to SARM indirectly, for example, using a component in addition to SARM and the test compound, wherein the additional component binds to SARM in the absence of the compound, and wherein this binding of the compound to SARM is reduced by a test compound that also binds to SARM.

[0010] In yet further aspects, the disclosure includes methods for identifying compounds that inhibit SARM activity and/or expression that involve providing or obtaining a sample containing SARM, contacting the sample containing SARM with a test compound, and measuring the transcriptional activity of SARM, wherein a decrease in the transcriptional activity of SARM in the presence of the compound indicates that the compound is a candidate compound that inhibits SARM activity and/or expression. Measuring the transcriptional activity of SARM can include measuring SARM transcriptional activity (e.g., using a genetic reporter construct containing a SARM promoter, or a biologically active portion of a SARM promoter, operably linked to a reporter, such as a nucleic acid sequence encoding a detectable protein (e.g., a fluorescent protein (e.g., green fluorescent protein) or an enzyme, such as luciferase (e.g., firefly luciferase)). Such methods can be high-throughput.

[0011] In additional aspects, the disclosure includes methods for identifying compounds that inhibit SARM activity and/or expression that involve contacting or treating a neuron (e.g., a cultured neuron) with a candidate compound identified via the *in silico* or *in vitro* methods disclosed herein, e.g., to confirm that the candidate compound reduces axonal and/or synaptic degradation in injured neurons. In other embodiments, compounds applied in such methods are not first identified via the *in silico* or *in vitro* methods disclosed herein. Either way, the methods can include injuring the neuron, for example, by axotomizing the neuron, and determining whether axonal and/or synaptic degradation is altered in the presence of the candidate compound relative to axonal degradation in the absence of the compound, wherein a decrease in axonal and/or synaptic degradation indicates that the candidate compound is a compound that inhibits SARM activity and/or expression. In some embodiments, the neuron is contacted or treated with the compound before injury. In other embodiments, the neuron is contacted or treated with the compound after injury.

[0012] In other aspects, the disclosure includes administering a compound to an animal model of neurodegenerative disease to allow assessment or verification of whether the compound can be used to treat neurodegenerative disease and/or whether the compound inhibits SARM activity and/or expression in the animal model.

[0013] Any of the methods for identifying compounds that modulate SARM can include, where appropriate, conducting control experiments to confirm positive observation and/or to identify and/or exclude false positives.

[0014] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Methods and materials are described herein for use in the present invention; other, suitable methods and materials known in the art can also be used. The materials, methods, and examples are illustrative only and not intended to be limiting. All publications, patent applications, patents,

sequences, database entries, and other references mentioned herein are incorporated by reference in their entirety. In case of conflict, the present specification, including definitions, will control.

[0015] Other features and advantages of the invention will be apparent from the following detailed description and figures, and from the claims.

DESCRIPTION OF DRAWINGS

[0016] FIGS. 1A-I. Identification of three mutations that suppress Wallerian degeneration *in vivo*. A. ORN MARCM clones in control, l(3)896, l(3)4621, and l(3)4705. Right, axotomy; left, uninjured control. Boxed regions are enlarged at right. n \geq 15. B. Control and l(3)896 brains 30 days after injury. n \geq 10. C. l(3)896 clones 50 days after injury. n=11. D. Control ORN MARCM clones labeled with UAS-nSyb::GFP, uninjured (top) and 30 days after axotomy (bottom). n \geq 15. E. l(3)896 MARCM clones labeled with UAS-nSyb::GFP, uninjured (top) and 30 days after axotomy (bottom). n \geq 15. F. MARCM clones in mushroom body (MB) Y neurons in control and l(3)896 backgrounds at the indicated developmental stages. dorsal (d) and medial (m) axonal branches (arrows), and dendrites (circled). n \geq 15 for all. G. dMP2 neurons with GFP. Ventral views (anterior up) of stage 16 embryos (left) and 1st instar larvae. dMP2 neurons before (arrows) and after (arrowheads) segment-specific apoptosis. n \geq 20 at each time point. H. Wild type and l(3)896 mutant clones with (right) or without (left) ectopic expression of hid. n \geq 20. I. Wild type and l(3)896 mutant clones in the eye-antennal disc of 3rd instar larvae. Homozygous mutant clones are labeled as GFP-negative (circled). Red, TUNEL staining n \geq 10.

[0017] FIGS. 2A-D. Mutations in *dsarm* block Wallerian degeneration. A. The lethality of l(3)896, l(3)4621, and l(3)4705 was mapped to region 66B. B. The locations of the point mutations in *dsarm* that block axon degeneration and their corresponding resulting protein change. C. *Dsarm* protein domains, positions and effect of predicted point mutations. D. UAS-*dsarm* in l(3)896 mutant clones or a *dsarm*⁺ BAC rescue axonal degeneration defects in l(3)896/l(3)4621 animals. n=12.

[0018] FIGS. 3A-H. *Sarm1* ^{-/-} primary cultures are protected from Wallerian degeneration but not NGF withdrawal-induced axonal degeneration. A. Phase contrast images of SCG explant cultures from wild type (top), *Sarm1* ^{-/-} (middle), and *Wld^S* expressing (bottom) animals at the indicated time after axotomy. B. Quantification from A. Mean \pm SEM, *p<0.01. C. Axon preservation at the indicated time points in cortical neuron cultures from E16.5 mouse embryos. a-Tau, red. D. Quantification from C. Mean \pm SEM, *p<0.01. E. Axon preservation at the indicated time points in DRG cultures from E13.5 mouse embryos. a-TUJI, green. F. Quantification from E. Mean \pm SEM, *p<0.01. G. DRG explant cultures from E13.5 mouse embryos after NGF withdrawal at the indicated time points. a-TUJI, green. H. Quantification from G. Mean \pm SEM, *p<0.01.

[0019] FIGS. 4A-F. *Sarm1* is required for Wallerian degeneration in mice *in vivo*. A. Sciatic nerve distal to the injury site stained with Toluidine blue. Time points and genotypes as indicated. B. Ultra-structural analysis of *Sarm1* ^{+/-} and *Sarm1* ^{-/-} axons before or 14 days after axotomy. my, myelin; nf, neurofilaments, m, mitochondrion. C. NMJ preservation at tibialis anterior muscles. red, AChR (post synapse/muscle); green, NF-M/synpatophysin (presynapse). D. Immunoblot analysis of distal injured nerve segment. n=4 at each time-

point and genotype. E. Quantification from A. n=5 for all. (p=0.0002) F. Quantification from C. n>200 synapses for each genotype and time point.

[0020] FIGS. 5A-B. Crossing schemes for EMS mutant lines and generating MARCM lines for screening A. Crossing scheme for generating a collection of ~2000 mutant stocks, each with a unique EMS-mutagenized third chromosome containing FRT sites on each arm. B. Scheme for generating MARCM clones and screening mutants for phenotypes in OR22a-positive neurons using ey-flp.

[0021] FIGS. 6A-B. Sarm1 knockout mice are protected from axon degeneration after sciatic nerve lesion in vivo. Right sciatic nerves were lesioned in 6-8 week old Sarm1 -/- or Sarm1 +/- mice. A. Transected nerves were stained for neurofilament-M as a marker of structure integrity of the injured axon at the indicated time points. n=4 mice for all. Values are presented as mean±SEM, *p<0.01. B. Macrophage/monocyte infiltration into transected nerves was assayed by staining for CD11b (macrophages) and DAPI (all cells) at the indicated time points after lesion. n=4 mice for all. Values are presented as mean±SEM, *p<0.01.

DETAILED DESCRIPTION

[0022] The present disclosure is based, inter alia, on the surprising discovery that the *Drosophila* Toll receptor adaptor dSarm (sterile α /Armadillo/Toll-Interleukin receptor homology domain protein) promotes axon destruction, and that loss of dSarm function can cell-autonomously suppress the degeneration of severed axons for the lifespan of the fly. Pro-degenerative Sarm1 function is conserved in mice, where transected Sarm1 null axons exhibit remarkable long-term survival both in vivo and in vitro. Neurons undergoing axonal and/or synaptic degradation (e.g., a process known as Wallerian degeneration) benefit from the modulation (e.g., inhibition) of Sterile α and HEAT/Armadillo Motifs Containing Protein (SARM, also commonly referred to in the art as MyD88-5) expression and/or function. Specifically, injured neurons show reduced axonal and synaptic degradation (e.g., Wallerian degeneration) following injury (axotomy) when SARM is reduced in the neuron. Furthermore, Wallerian degeneration in injured neurons was apparently halted in injured neurons leading to axonal and/or synaptic repair. Accordingly, the present disclosure provides compositions and methods for treating a subject with or at risk of a neurological disorder that manifests and/or includes axonal and/or synaptic degradation (e.g., Wallerian degeneration) by targeting and thereby modulating (e.g., inhibiting) SARM (e.g., SARM1) to reduce axonal and/or synaptic degradation in the subject.

[0023] Data leading to the present disclosure includes generation and functional analysis of four distinct loss-of-function genetic mutations that maintain, improve, or enhance the structure and/or function of axons and/or synapses post axonal injury in *Drosophila*. As shown herein, each of the four mutations map to the *Drosophila* homologue of mammalian SARM (SARM1), dSARM.

[0024] dSarm is reportedly most similar to mammalian SARM, SARM1 (Mink et al., *Genomics*, 74:234-244, 2001). A single SARM gene has been identified in *Caenorhabditis elegans*, *Drosophila*, mouse, and human and its sequence is conserved among these species. SARM is generally functionally associated with the host immune response. Specifically, SARM is reported to be negative regulator of Toll receptor signaling (O'Neil et al., *Trends Immunol.*, 24:286-290,

2003). Reports also describe a functional role of SARM in the regulation of neuronal survival/death. For example, murine SARM is reportedly predominantly expressed in neurons and is involved in the regulation of neuronal death in response to oxygen glucose deprivation and exposure of neurons to the Parkinsonian neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) (Kim et al., *JEM*, 204: 2063-2074, 2007 and Kim et al., Abstract from the To112008 meeting conducted in Lisbon, Portugal from Sep. 24-27, 2008, entitled Distinctive role of MyD88-5 (SARM) in neurodegeneration and host defense). A role for SARM has also been described in neuronal development (Yuan et al., *J. Immunol.*, 184:6874-6881, 2010). Reviews on this subject are available (see, e.g., Dalod, *Science Signaling*, 417:1-3, 2007).

Compositions and Methods for Modulating SARM

[0025] The disclosure includes compositions and methods for modulating (e.g., inhibiting) SARM expression (e.g., protein and/or nucleic acid (mRNA) expression) and/or activity (e.g., protein activity). Such compositions and methods generally include targeting (e.g., specifically targeting) SARM DNA, mRNA, and/or protein to thereby modulate (e.g., inhibit) SARM mRNA and/or protein expression and/or function. In some instances, targeting (e.g., specifically targeting) SARM can include targeting (e.g., specifically targeting) SARM in a neuron (including in the neuronal cell body), in an axon, in a synapse, and/or in a dendrite. SARM can additionally be targeted in non-neuronal cells, including cells of the immune system, as long as SARM is targeted in a neuron (including in the neuronal cell body), in an axon, in a synapse, and/or in a dendrite.

[0026] SARM included in the present disclosure includes *C. elegans*, *Drosophila*, and mammalian (e.g., mouse and human (e.g., SARM1)) SARM DNA, mRNA, and/or protein, including full length transcripts and proteins, truncated transcripts and proteins (e.g., truncated SARM transcripts and proteins that exhibit or have detectable SARM activity), and/or mutant or mutated SARM transcripts and protein, truncated or otherwise (e.g., that exhibit or have detectable SARM activity). The term SARM also refers to and includes synonyms of SARM (synonyms can be viewed at, e.g., ihopnet.org).

[0027] In some instances, SARM can include SEQ ID NO:1 (human SARM1 mRNA (national center for biotechnology information (NCBI) accession number NM_015077 (NM_015077.2)); SEQ ID NO:2 (human SARM1 protein (NCBI accession number NP_055892 (NP_055892.2)); SEQ ID NO:3 (murine SARM1 mRNA, isoform 1 (NCBI accession number NM_001168521 (NM_001168521.1)); SEQ ID NO:4 (murine SARM1 protein, isoform 1 (NCBI accession number NP_001161993 (NP_001161993.1)); SEQ ID NO:5 (murine SARM1 mRNA, isoform 2 (NCBI accession number NM_172795 (NM_172795.3)); and/or SEQ ID NO:6 (murine SARM1 protein, isoform 2 (NCBI accession number NP_766383 (NP_766383.2)). Accordingly, the present disclosure provides compositions and methods for treating a subject with or at risk of a neurological disorder that manifests and/or includes axonal and/or synaptic degradation by targeting (e.g., specifically targeting) one or more of SEQ ID NOs: 1, 2, 3, 4, 5, and/or 6 in a neuron (including in the neuronal cell body), in an axon, in a synapse, and/or in a dendrite, thereby modulating (e.g., inhibiting) SARM (e.g., SARM1) to reduce axonal and/or synaptic degradation in the subject.

[0028] SARM can also include SARM-like nucleic acid and amino acid sequences with certain percent identity to SEQ ID NOs: 1, 2, 3, 4, 5, and/or 6. Suitable identity can include, for example, 50%, 60%, 70%, 80%, 85%, 90%, 95%, 98%, 99%, and 100% identity between SEQ ID NOs: 1, 2, 3, 4, 5, and/or 6 and the SARM-like sequence.

[0029] Methods for determining percent identity between nucleic acid and amino acid sequences are known in the art. For example, the sequences are aligned for optimal comparison purposes (e.g., gaps can be introduced in one or both of a first and a second amino acid or nucleic acid sequence for optimal alignment and non-homologous sequences can be disregarded for comparison purposes). In a preferred embodiment, the length of a reference sequence aligned for comparison purposes is at least 30%, preferably at least 40%, more preferably at least 50%, even more preferably at least 60%, and even more preferably at least 70%, 80%, 90%, or 100% of the length of the reference sequence. The amino acid residues or nucleotides at corresponding amino acid positions or nucleotide positions are then compared. When a position in the first sequence is occupied by the same amino acid residue or nucleotide as the corresponding position in the second sequence, then the molecules are identical at that position. The determination of percent identity between two amino acid sequences is accomplished using the BLAST 2.0 program. Sequence comparison is performed using an ungapped alignment and using the default parameters (Blossom 62 matrix, gap existence cost of 11, per residue gapped cost of 1, and a lambda ratio of 0.85). The mathematical algorithm used in BLAST programs is described in Altschul et al. (Nucleic Acids Res. 25:3389-3402, 1997).

[0030] Compositions for modulating SARM expression and/or activity can include, but are not limited to, one or more of: small molecules, inhibitory nucleic acids, antibodies, and inhibitory peptides. For example, one or more of a small molecule, an inhibitory nucleic acid, an anti-SARM antibody, and/or an inhibitory nucleic acid can be used to target (e.g., specifically target) SARM (e.g., SEQ ID NOs: 1, 2, 3, 4, 5, and/or 6) in a neuron (including in the neuronal cell body), in an axon, in a synapse, and/or in a dendrite, thereby modulating (e.g., inhibiting) SARM (e.g., SARM1) to reduce axonal and/or synaptic degradation in the subject.

[0031] Small Molecules

[0032] Suitable small molecules include small molecules that inhibit SARM expression and/or activity directly, indirectly, or both directly and indirectly. Suitable small molecules include small molecules that bind (e.g., bind specifically) to SARM and thereby inhibit SARM expression and/or activity, and/or small molecules that do not bind to SARM or that bind to SARM with low affinity, but that inhibit SARM expression and/or activity by binding to a component of the SARM signaling pathway upstream or downstream of SARM.

[0033] Inhibitory Nucleic Acids

[0034] Inhibitory Nucleic Acids suitable for use in the methods described herein include inhibitory nucleic acids that bind (e.g., bind specifically) to SARM. Also encompassed are inhibitory nucleic acids that bind (e.g., bind specifically) to a component of the SARM signaling pathway upstream or downstream of SARM. Exemplary inhibitory nucleic acids include, but are not limited to, siRNA and antisense nucleic acids. For example, the disclosure includes siRNA and antisense nucleic acids that target or bind (e.g., specifically target or specifically bind) to SARM mRNA (e.g.,

SEQ ID NOs: 1, 3, and/or 5 and/or a nucleic acid sequence encoding SEQ ID NOs: 2, 4, or 6) in a neuron (including in the neuronal cell body), in an axon, in a synapse, and/or in a dendrite, thereby modulating (e.g., inhibiting) SARM (e.g., SARM1) to reduce axonal and/or synaptic degradation in the subject.

[0035] RNAi is a process whereby double-stranded RNA (dsRNA, also referred to herein as siRNAs or ds siRNAs, for double-stranded small interfering RNAs,) induces the sequence-specific degradation of homologous mRNA in animals and plant cells (Hutvagner and Zamore, *Curr. Opin. Genet. Dev.*: 12, 225-232 (2002); Sharp, *Genes Dev.*, 15:485-490 (2001)). In mammalian cells, RNAi can be triggered by 21-nucleotide (nt) duplexes of small interfering RNA (siRNA) (Chiu et al, *Mol. Cell.* 10:549-561 (2002); Elbashir et al, *Nature* 411 :494-498 (2001)), or by micro-RNAs (miRNA), functional small-hairpin RNA (shRNA), or other dsRNAs which are expressed in vivo using DNA templates with RNA polymerase III promoters (Zeng et al, *Mol. Cell* 9: 1327-1333 (2002); Paddison et al, *Genes Dev.* 16:948-958 (2002); Lee et al, *Nature Biotechnol.* 20:500-505 (2002); Paul et al, *Nature Biotechnol.* 20:505-508 (2002); Tuschl, T., *Nature Biotechnol.* 20:440-448 (2002); Yu et al, *Proc. Natl. Acad. Sci. USA* 99(9):6047-6052 (2002); McManus et al, *RNA* 8:842-850 (2002); Sui et al, *Proc. Natl. Acad. Sci. USA* 99(6):5515-5520 (2002)).

[0036] RNAi useful for inhibiting SARM can include dsRNA molecules comprising 16-30, e.g., 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 nucleotides in each strand, wherein one of the strands is substantially identical, e.g., at least 80% (or more, e.g., 85%, 90%, 95%, or 100%) identical, e.g., having 3, 2, 1, or 0 mismatched nucleotide(s), to a target region in the mRNA, and the other strand is complementary to the first strand. The dsRNA molecules can be chemically synthesized, or can be transcribed in vitro from a DNA template, or in vivo from, e.g., shRNA. The dsRNA molecules can be designed using any method known in the art; a number of algorithms are known, and are commercially available. Gene walk methods can be used to optimize the inhibitory activity of the siRNA. Inhibitory nucleic acids can include both siRNA and modified siRNA derivatives, e.g., siRNAs modified to alter a property such as the pharmacokinetics of the composition, for example, to increase half-life in the body, as well as engineered RNAi precursors.

[0037] siRNA can be delivered into cells by methods known in the art, e.g., cationic liposome transfection and electroporation. Direct delivery of siRNA in saline or other excipients can silence target genes in tissues, such as the eye, lung, and central nervous system (Bitko et al., *Nat. Med.* 11:50-55 (2005); Shen et al., *Gene Ther.* 13:225-234 (2006); Thakker, et al., *Proc. Natl. Acad. Sci. U.S.A.* (2004)). In adult mice, efficient delivery of siRNA can be accomplished by "high-pressure" delivery technique, a rapid injection (within 5 seconds) of a large volume of siRNA containing solution into animal via the tail vein (Liu (1999), supra; McCaffrey (2002), supra; Lewis, *Nature Genetics* 32:107-108 (2002)). Liposomes and nanoparticles can also be used to deliver siRNA into animals. Delivery methods using liposomes, e.g. stable nucleic acid-lipid particles (SNALPs), dioleoyl phosphatidylcholine (DOPC)-based delivery system, as well as lipoplexes, e.g. Lipofectamine 2000, TransIT-TKO, have been shown to effectively repress target mRNA (de Fougères, *Human Gene Ther.* 19:125-132 (2008); Landen et al., *Cancer Res.* 65:6910-6918 (2005); Luo et al., *Mol. Pain.* 1:29

(2005); Zimmermann et al., *Nature* 441:111-114 (2006)). Conjugating siRNA to peptides, RNA aptamers, antibodies, or polymers, e.g. dynamic polyconjugates, cyclodextrin-based nanoparticles, atelocollagen, and chitosan, can improve siRNA stability and/or uptake. (Howard et al., *Mol. Ther.* 14:476-484 (2006); Hu-Lieskovan et al., *Cancer Res.* 65:8984-8992 (2005); Kumar, et al., *Nature* 448:39-43; McNamara et al., *Nat. Biotechnol.* 24:1005-1015 (2007); Rozema et al., *Proc. Natl. Acad. Sci. U.S.A.* 104:12982-12987 (2007); Song et al., *Nat. Biotechnol.* 23:709-717 (2005); Soutschek (2004), supra; Wolfium et al., *Nat. Biotechnol.* 25:1149-1157 (2007)). Viral-mediated delivery mechanisms can also be used to induce specific silencing of targeted genes through expression of siRNA, for example, by generating recombinant adenoviruses harboring siRNA under RNA Pol II promoter transcription control (Xia et al. (2002), supra). Infection of HeLa cells by these recombinant adenoviruses allows for diminished endogenous target gene expression. Injection of the recombinant adenovirus vectors into transgenic mice expressing the target genes of the siRNA results in *in vivo* reduction of target gene expression. Id. In an animal model, whole-embryo electroporation can efficiently deliver synthetic siRNA into post-implantation mouse embryos (Calegari et al., *Proc. Natl. Acad. Sci. USA* 99(22): 14236-40 (2002)).

[0038] siRNA duplexes can be expressed within cells from engineered RNAi precursors, e.g., recombinant DNA constructs using mammalian Pol III promoter systems (e.g., H1 or U6/snRNA promoter systems (Tuschl (2002), supra) capable of expressing functional double-stranded siRNAs; (Bagella et al., *J. Cell. Physiol.* 177:206-213 (1998); Lee et al. (2002), supra; Miyagishi et al. (2002), supra; Paul et al. (2002), supra; Yu et al. (2002), supra; Sui et al. (2002), supra). Transcriptional termination by RNA Pol III occurs at runs of four consecutive T residues in the DNA template, providing a mechanism to end the siRNA transcript at a specific sequence. The siRNA is complementary to the sequence of the target gene in 5'-3' and 3'-5' orientations, and the two strands of the siRNA can be expressed in the same construct or in separate constructs. Hairpin siRNAs, driven by H1 or U6 snRNA promoter and expressed in cells, can inhibit target gene expression (Bagella et al. (1998), supra; Lee et al. (2002), supra; Miyagishi et al. (2002), supra; Paul et al. (2002), supra; Yu et al. (2002), supra; Sui et al. (2002) supra). Constructs containing siRNA sequence under the control of T7 promoter also make functional siRNAs when cotransfected into the cells with a vector expression T7 RNA polymerase (Jacque (2002), supra).

[0039] Synthetic siRNAs can be delivered into cells, e.g., by direct delivery, cationic liposome transfection, and electroporation. However, these exogenous siRNA typically only show short term persistence of the silencing effect (4.about.5 days). Several strategies for expressing siRNA duplexes within cells from recombinant DNA constructs allow longer-term target gene suppression in cells, including mammalian Pol II and III promoter systems (e.g., H1, U1, or U6/snRNA promoter systems (Denti et al. (2004), supra; Tuschl (2002), supra); capable of expressing functional double-stranded siRNAs (Bagella et al., *J. Cell. Physiol.* 177:206-213 (1998); Lee et al. (2002), supra; Miyagishi et al. (2002), supra; Paul et al. (2002), supra; Scherer et al. (2007), supra; Yu et al. (2002), supra; Sui et al. (2002), supra).

[0040] Transcriptional termination by RNA Pol III occurs at runs of four consecutive T residues in the DNA template,

providing a mechanism to end the siRNA transcript at a specific sequence. The siRNA is complementary to the sequence of the target gene in 5'-3' and 3'-5' orientations, and the two strands of the siRNA can be expressed in the same construct or in separate constructs. Hairpin siRNAs, driven by H1 or U6 snRNA promoter and expressed in cells, can inhibit target gene expression (Bagella et al. (1998), supra; Lee et al. (2002), supra; Miyagishi et al. (2002), supra; Paul et al. (2002), supra; Yu et al. (2002), supra; Sui et al. (2002) supra). Constructs containing siRNA sequence under the control of T7 promoter also make functional siRNAs when cotransfected into the cells with a vector expression T7 RNA polymerase (Jacque (2002), supra).

[0041] siRNA can also be expressed in a miRNA backbone which can be transcribed by either RNA Pol II or III. MicroRNAs are endogenous noncoding RNAs of approximately 22 nucleotides in animals and plants that can post-transcriptionally regulate gene expression (Bartel, *Cell* 116:281-297 (2004); Valencia-Sanchez et al., *Genes & Dev.* 20:515-524 (2006)). One common feature of miRNAs is that they are excised from an approximately 70 nucleotide precursor RNA stem loop by Dicer, an RNase III enzyme, or a homolog thereof. By substituting the stem sequences of the miRNA precursor with the sequence complementary to the target mRNA, a vector construct can be designed to produce siRNAs to initiate RNAi against specific mRNA targets in mammalian cells. When expressed by DNA vectors containing polymerase II or III promoters, miRNA designed hairpins can silence gene expression (McManus (2002), supra; Zeng (2002), supra).

[0042] Engineered RNA precursors, introduced into cells or whole organisms as described herein, will lead to the production of a desired siRNA molecule. Such an siRNA molecule will then associate with endogenous protein components of the RNAi pathway to bind to and target a specific mRNA sequence for cleavage, destabilization, and/or translation inhibition destruction. In this fashion, the mRNA to be targeted by the siRNA generated from the engineered RNA precursor will be depleted from the cell or organism, leading to a decrease in the concentration of the protein encoded by that mRNA in the cell or organism.

[0043] An "antisense" nucleic acid can include a nucleotide sequence that is complementary to a "sense" nucleic acid encoding a protein, e.g., complementary to the coding strand of a double-stranded cDNA molecule or complementary to a PKCd mRNA sequence. The antisense nucleic acid can be complementary to an entire coding strand of a target sequence, or to only a portion thereof. In another embodiment, the antisense nucleic acid molecule is antisense to a "noncoding region" of the coding strand of a nucleotide sequence (e.g., the 5' and 3' untranslated regions).

[0044] An antisense nucleic acid can be designed such that it is complementary to the entire coding region of a target mRNA, but can also be an oligonucleotide that is antisense to only a portion of the coding or noncoding region of the target mRNA. For example, the antisense oligonucleotide can be complementary to the region surrounding the translation start site of the target mRNA, e.g., between the -10 and +10 regions of the target gene nucleotide sequence of interest. An antisense oligonucleotide can be, for example, about 7, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, or more nucleotides in length.

[0045] An antisense nucleic acid can be constructed using chemical synthesis and enzymatic ligation reactions using

procedures known in the art. For example, an antisense nucleic acid (e.g., an antisense oligonucleotide) can be chemically synthesized using naturally occurring nucleotides or variously modified nucleotides designed to increase the biological stability of the molecules or to increase the physical stability of the duplex formed between the antisense and sense nucleic acids, e.g., phosphorothioate derivatives and acridine substituted nucleotides can be used. The antisense nucleic acid also can be produced biologically using an expression vector into which a nucleic acid has been subcloned in an antisense orientation (i.e., RNA transcribed from the inserted nucleic acid will be of an antisense orientation to a target nucleic acid of interest, described further in the following subsection). Based upon the sequences disclosed herein, one of skill in the art can easily choose and synthesize any of a number of appropriate antisense molecules for use in accordance with the present invention. For example, a “gene walk” comprising a series of oligonucleotides of 15-30 nucleotides spanning the length of a target nucleic acid can be prepared, followed by testing for inhibition of target gene expression. Optionally, gaps of 5-10 nucleotides can be left between the oligonucleotides to reduce the number of oligonucleotides synthesized and tested. Such methods can also be used to identify siRNAs.

[0046] In some embodiments, the antisense nucleic acid molecule is a cc-anomeric nucleic acid molecule. A cc-anomeric nucleic acid molecule forms specific double-stranded hybrids with complementary RNA in which, contrary to the usual β -units, the strands run parallel to each other (Gaultier et al., *Nucleic Acids. Res.* 15:6625-6641 (1987)). The antisense nucleic acid molecule can also comprise a 2'-o-methylribose nucleotide (Inoue et al. *Nucleic Acids Res.* 15:6131-6148 (1987)) or a chimeric RNA-DNA analogue (Inoue et al. *FEBS Lett.*, 215:327-330 (1987)).

[0047] In some embodiments, the antisense nucleic acid is a morpholino oligonucleotide (see, e.g., Heasman, *Dev. Biol.* 243:209-14 (2002); Iversen, *Curr. Opin. Mol. Ther.* 3:235-8 (2001); Summerton, *Biochim. Biophys. Acta.* 1489: 141-58 (1999)).

[0048] Target gene expression can be inhibited by targeting nucleotide sequences complementary to a regulatory region (e.g., promoters and/or enhancers) to form triple helical structures that prevent transcription of the Spt5 gene in target cells. See generally, Helene, *Anticancer Drug Des.* 6:569-84 (1991); Helene, *C. Ann. N. Y. Acad. Sci.* 660:27-36 (1992); and Maher, *Bioassays* 14:807-15 (1992). The potential sequences that can be targeted for triple helix formation can be increased by creating a so called “switchback” nucleic acid molecule. Switchback molecules are synthesized in an alternating 5'-3', 3'-5' manner, such that they base pair with first one strand of a duplex and then the other, eliminating the necessity for a sizeable stretch of either purines or pyrimidines to be present on one strand of a duplex.

[0049] Antisense nucleic acid molecules of the invention can be administered to a subject (e.g., by direct injection at a tissue site), or generated in situ such that they hybridize with or bind to cellular mRNA and/or genomic DNA encoding a target protein to thereby inhibit expression of the protein, e.g., by inhibiting transcription and/or translation. Alternatively, antisense nucleic acid molecules can be modified to target selected cells and then administered systemically. For systemic administration, antisense molecules can be modified such that they specifically bind to receptors or antigens expressed on a selected cell surface, e.g., by linking the anti-

sense nucleic acid molecules to peptides or antibodies that bind to cell surface receptors or antigens. The antisense nucleic acid molecules can also be delivered to cells using the vectors described herein. To achieve sufficient intracellular concentrations of the antisense molecules, vector constructs in which the antisense nucleic acid molecule is placed under the control of a strong pol II or pol III promoter can be used.

[0050] Additional information regarding antisense technologies and their use in vivo can be found in Crooke, *Antisense Drug Technology: Principles, Strategies and Applications*, (CRC Press, 2007).

[0051] Locked Nucleic Acids

[0052] LNAs comprise ribonucleic acid analogues wherein the ribose ring is “locked” by a methylene bridge between the 2'-oxygen and the 4'-carbon—i.e., oligonucleotides containing at least one LNA monomer, that is, one 2'-O,4'-C-methylene- β -D-ribofuranosyl nucleotide. LNA bases form standard Watson-Crick base pairs but the locked configuration increases the rate and stability of the basepairing reaction (Jepsen et al., *Oligonucleotides*, 14, 130-146 (2004)). LNAs also have increased affinity to base pair with RNA as compared to DNA. These properties render LNAs especially useful as probes for fluorescence in situ hybridization (FISH) and comparative genomic hybridization, as knockdown tools for miRNAs, and as antisense oligonucleotides to block mRNA translation.

[0053] The LNA molecules can include molecules comprising 10-30, e.g., 12-24, e.g., 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 nucleotides in each strand, wherein one of the strands is substantially identical, e.g., at least 80% (or more, e.g., 85%, 90%, 95%, or 100%) identical, e.g., having 3, 2, 1, or 0 mismatched nucleotide(s), to a target region in the lncRNA. The LNA molecules can be chemically synthesized using methods known in the art.

[0054] The LNA molecules can be designed using any method known in the art; a number of algorithms are known, and are commercially available (e.g., on the internet, for example at exiqon.com). See, e.g., You et al., *Nuc. Acids. Res.* 34:e60 (2006); McTigue et al., *Biochemistry* 43:5388-405 (2004); and Levin et al., *Nuc. Acids. Res.* 34:e142 (2006). For example, “gene walk” methods, similar to those used to design antisense oligos, can be used to optimize the inhibitory activity of the LNA; for example, a series of oligonucleotides of 10-30 nucleotides spanning the length of a target lncRNA can be prepared, followed by testing for activity. Optionally, gaps, e.g., of 5-10 nucleotides or more, can be left between the LNAs to reduce the number of oligonucleotides synthesized and tested. GC content is preferably between about 30-60%. General guidelines for designing LNAs are known in the art; for example, LNA sequences will bind very tightly to other LNA sequences, so it is preferable to avoid significant complementarity within an LNA. Contiguous runs of three or more Gs or Cs, or more than four LNA residues, should be avoided where possible (for example, it may not be possible with very short (e.g., about 9-10 nt) oligonucleotides). In some embodiments, the LNAs are xylo-LNAs.

[0055] In some embodiments, the LNA molecules can be designed to target a specific region of the lncRNA. For example, a specific functional region can be targeted, e.g., a region comprising a known RNA localization motif (i.e., a region complementary to the target nucleic acid on which the lncRNA acts), or a region comprising a known protein binding region, e.g., a Polycomb (e.g., Polycomb Repressive Complex 2 (PRC2), comprised of H3K27 methylase EZH2,

SUZ12, and EED)) or LSD1/CoREST/REST complex binding region (see, e.g., Tsai et al., *Science*. 2010 Aug. 6; 329 (5992):689-93. Epub 2010 Jul. 8; and Zhao et al., *Science*. 2008 Oct. 31; 322(5902):750-6). Alternatively or in addition, highly conserved regions can be targeted, e.g., regions identified by aligning sequences from disparate species such as primate (e.g., human) and rodent (e.g., mouse) and looking for regions with high degrees of identity. Percent identity can be determined routinely using basic local alignment search tools (BLAST programs) (Altschul et al., *J. Mol. Biol.*, 1990, 215, 403-410; Zhang and Madden, *Genome Res.*, 1997, 7, 649-656), e.g., using the default parameters.

[0056] For additional information regarding LNAs see U.S. Pat. Nos. 6,268,490; 6,734,291; 6,770,748; 6,794,499; 7,034,133; 7,053,207; 7,060,809; 7,084,125; and 7,572,582; and U.S. Pre-Grant Pub. Nos. 20100267018; 20100261175; and 20100035968; Koshkin et al. *Tetrahedron* 54, 3607-3630 (1998); Obika et al. *Tetrahedron Lett.* 39, 5401-5404 (1998); Jepsen et al., *Oligonucleotides* 14:130-146 (2004); Kauppinen et al., *Drug Disc. Today* 2(3):287-290 (2005); and Ponting et al., *Cell* 136(4):629-641 (2009), and references cited therein.

[0057] Ribozymes

[0058] Ribozymes suitable for use in methods encompassed by the present disclosure include ribozymes that recognize and/or cleave SARM and/or components of the SARM signaling pathway upstream or downstream of SARM. For example, the disclosure includes ribozymes that recognize and/or cleave SARM mRNA (e.g., SEQ ID NOs: 1, 3, and/or 5 and/or a nucleic acid sequence encoding SEQ ID NOs: 2, 4, or 6) in a neuron (including in the neuronal cell body), in an axon, in a synapse, and/or in a dendrite, thereby modulating (e.g., inhibiting) SARM (e.g., SARM1) to reduce axonal and/or synaptic degradation in the subject.

[0059] Ribozymes are a type of RNA that can be engineered to enzymatically cleave and inactivate other RNA targets in a specific, sequence-dependent fashion. By cleaving the target RNA, ribozymes inhibit translation, thus preventing the expression of the target gene. Ribozymes can be chemically synthesized in the laboratory and structurally modified to increase their stability and catalytic activity using methods known in the art. Alternatively, ribozyme genes can be introduced into cells through gene-delivery mechanisms known in the art. A ribozyme having specificity for a target nucleic acid can include one or more sequences complementary to the nucleotide sequence of a cDNA described herein, and a sequence having known catalytic sequence responsible for mRNA cleavage (see U.S. Pat. No. 5,093,246 or Haselhoff and Gerlach *Nature* 334:585-591 (1988)). For example, a derivative of a *Tetrahymena* L-19 IVS RNA can be constructed in which the nucleotide sequence of the active site is complementary to the nucleotide sequence to be cleaved in a target mRNA (Cech et al. U.S. Pat. No. 4,987,071; and Cech et al. U.S. Pat. No. 5,116,742). Alternatively, target mRNA can be used to select a catalytic RNA having a specific ribonuclease activity from a pool of RNA molecules (Bartel and Szostak, *Science* 261: 1411-1418 (1993)).

[0060] Aptamers

[0061] Aptamers suitable for use in methods encompassed by the present disclosure include aptamers that bind (e.g., bind specifically) to SARM and/or components of the SARM signaling pathway upstream or downstream of SARM. For example, the disclosure includes aptamers that bind (e.g., bind specifically) to SARM amino acid sequences (e.g., SEQ

ID NOs: 2, 4, and/or 6) in a neuron (including in the neuronal cell body), in an axon, in a synapse, and/or in a dendrite, thereby modulating (e.g., inhibiting) SARM (e.g., SARM1) to reduce axonal and/or synaptic degradation in the subject.

[0062] Aptamers are short oligonucleotide sequences which can specifically bind specific proteins. It has been demonstrated that different aptameric sequences can bind specifically to different proteins, for example, the sequence GGNNGG where N=guanosine (G), cytosine (C), adenosine (A) or thymidine (T) binds specifically to thrombin (Bock et al (1992) *Nature* 355: 564 566 and U.S. Pat. No. 5,582,981 (1996) Toole et al). Methods for selection and preparation of such R A aptamers are known in the art (see, e.g., Famulok, *Curr. Opin. Struct. Biol.* 9:324 (1999); Herman and Patel, *J. Science* 287:820-825 (2000)); Kelly et al, *J. Mol. Biol.* 256: 417 (1996); and Feigon et al, *Chem. Biol.* 3: 611 (1996)).

[0063] Antibodies

[0064] The present disclosure also includes methods that include the use or administration of antibodies and antibody fragments that bind (e.g., bind specifically) to SARM (e.g., SEQ ID NOs: 2, 4, and or 6 and/or an epitope presented on native SARM (e.g., SEQ ID NOs: 2, 4, and or 6)) and thereby inhibit SARM activity in a neuron. Antibodies and antibody fragments that bind (e.g., bind specifically) epitopes expressed (e.g., specifically expressed) on the surface of a neuron such that when the epitope is bound by the antibody SARM expression and/or activity is reduced are also included in the present disclosure.

[0065] Inhibitory Peptides

[0066] Also included in the present disclosure are methods that include the use or administration of inhibitory peptides that bind (e.g., bind specifically) to SARM or interact with SARM and thereby inhibit SARM activity and/or expression in a neuron. Such peptides can bind or interact with an epitope on SARM and/or with a SARM domain. SARM domains that can be bound by inhibitory peptides include, but are not limited to, the alpha helical domain (e.g., including the interacting face of the SARM a helix) and/or the TIR domain. Suitable inhibitory peptides can that bind or interact with SARM can also be used to increase SARM degradation, for example, by increasing ubiquitination and/or proteosomal degradation of SARM.

[0067] Antibodies and inhibitory peptides can be modified to facilitate cellular uptake or increase in vivo stability. For example, acylation or PEGylation facilitates cellular uptake, increases bioavailability, increases blood circulation, alters pharmacokinetics, decreases immunogenicity and/or decreases the needed frequency of administration.

[0068] Methods for synthesizing suitable peptides are known in the art. For example, the peptides of this invention can be made by chemical synthesis methods, which are well known to the ordinarily skilled artisan. See, for example, Fields et al., Chapter 3 in *Synthetic Peptides: A User's Guide*, ed. Grant, W.H. Freeman & Co., New York, N.Y., 1992, p. 77. Hence, peptides can be synthesized using the automated Merrifield techniques of solid phase synthesis with the α -NH₂ protected by either t-Boc or Fmoc chemistry using side chain protected amino acids on, for example, an Applied Biosystems Peptide Synthesizer Model 430A or 431.

[0069] The terms "effective amount" and "effective to treat," as used herein, refer to an amount or a concentration of one or more compounds or a pharmaceutical composition described herein utilized for a period of time (including acute or chronic administration and periodic or continuous admin-

istration) that is effective within the context of its administration for causing an intended effect or physiological outcome.

[0070] Effective amounts of one or more compounds or a pharmaceutical composition for use in the present invention include amounts that inhibit SARM expression, levels (e.g., protein levels) and/or activity (e.g., biological activity) in neurons. An effective amount can also include an amount that inhibits or prevents Wallerian degeneration (e.g., axonal and/or synaptic degradation) in a neuron. For example, in the treatment of neurodegeneration, an effective amount of a compound includes a compound in an amount that improves to any degree or arrests any symptom of the disease. A therapeutically effective amount of a compound is not required to cure a disease but will provide a treatment for a disease.

[0071] In some embodiments, the present disclosure provides methods for using any one or more of the compositions (indicated below as 'X') disclosed herein in the following methods:

[0072] Substance X for use as a medicament in the treatment of one or more diseases or conditions disclosed herein (e.g., cancer, referred to in the following examples as 'Y'). Use of substance X for the manufacture of a medicament for the treatment of Y; and substance X for use in the treatment of Y.

[0073] Pharmaceutical Compositions

[0074] Pharmaceutical compositions typically include a pharmaceutically acceptable carrier. As used herein the language "pharmaceutically acceptable carrier" includes saline, solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like, compatible with pharmaceutical administration.

[0075] Pharmaceutical compositions are typically formulated to be compatible with its intended route of administration. Examples of routes of administration include systemic and local routes of administration. Exemplary routes include, but are not limited to, parenteral, e.g., intravenous, intradermal, subcutaneous, oral (e.g., inhalation), transdermal (topical), and transmucosal, administration. Methods of formulating suitable pharmaceutical compositions for each of these routes of administration are known in the art, see, e.g., the books in the series *Drugs and the Pharmaceutical Sciences: A Series of Textbooks and Monographs* (Dekker, N.Y.).

[0076] The pharmaceutical compositions can be included in a container, pack, or dispenser together with instructions for administration

[0077] Dosage

[0078] Effective amounts are discussed above. An effective amount can be administered in one or more administrations, applications or dosages. A therapeutically effective amount of a therapeutic compound (i.e., an effective dosage) depends on the therapeutic compounds selected. The compositions can be administered one from one or more times per day to one or more times per week; including once every other day. The skilled artisan will appreciate that certain factors may influence the dosage and timing required to effectively treat a subject, including but not limited to the severity of the disease or disorder, previous treatments, the general health and/or age of the subject, and other diseases present. Moreover, treatment of a subject with a therapeutically effective amount of the therapeutic compounds described herein can include a single treatment or a series of treatments.

[0079] Dosage, toxicity and therapeutic efficacy of the therapeutic compounds can be determined by standard pharmaceutical procedures in cell cultures or experimental ani-

mals, e.g., for determining the LD50 (the dose lethal to 50% of the population) and the ED50 (the dose therapeutically effective in 50% of the population). The dose ratio between toxic and therapeutic effects is the therapeutic index and it can be expressed as the ratio LD50/ED50. Compounds which exhibit high therapeutic indices are preferred. While compounds that exhibit toxic side effects may be used, care should be taken to design a delivery system that targets such compounds to the site of affected tissue in order to minimize potential damage to uninfected cells and, thereby, reduce side effects.

[0080] The data obtained from cell culture assays and animal studies can be used in formulating a range of dosage for use in humans. The dosage of such compounds lies preferably within a range of circulating concentrations that include the ED50 with little or no toxicity. The dosage may vary within this range depending upon the dosage form employed and the route of administration utilized. For any compound used in the method of the invention, the therapeutically effective dose can be estimated initially from cell culture assays. A dose may be formulated in animal models to achieve a circulating plasma concentration range that includes the IC50 (i.e., the concentration of the test compound which achieves a half-maximal inhibition of symptoms) as determined in cell culture. Such information can be used to more accurately determine useful doses in humans. Levels in plasma may be measured, for example, by high performance liquid chromatography. *Pharmaceutical Compositions and Methods of Administration*

Methods of Treatment/Personalized Medicine

[0081] The disclosure includes methods for treating a subject with or at risk of a neurological disorder that manifests and/or includes axonal and/or synaptic degradation (e.g., Wallerian degeneration) with a composition disclosed herein to target and thereby modulate (e.g., inhibit) SARM (e.g., SARM1) to reduce axonal and/or synaptic degradation in the subject.

[0082] As used herein, "treatment" means any manner in which one or more of the symptoms of a disease or disorder disclosed herein are ameliorated or otherwise beneficially altered. As used herein, amelioration of the symptoms of a particular disorder refers to any lessening, whether permanent or temporary, lasting or transient that can be attributed to or associated with treatment by the compositions and methods of the present invention. In some embodiments, treatment can promote or result in, for example, a decrease in the level or rate of axonal and/or synaptic degradation (e.g., Wallerian degeneration) in the subject relative to the level or rate prior to treatment; and/or reductions in one or more symptoms (e.g., a reduction in the severity of the symptoms) associated with the subject's disease in the subject relative to the subject's symptoms prior to treatment.

[0083] As mentioned above, neurodegeneration and neurodegenerative disorders include progressive structural and/or functional loss of nerve cells or neurons in the peripheral nervous system (PNS) and/or central nervous system (CNS). Many degenerative diseases or conditions are known to manifest and/or include axonal and/or synaptic degradation (e.g., Wallerian degeneration) and each of these diseases is suitable for treatment using the compositions and methods disclosed herein. Examples of neurodegenerative diseases that can be treated using the compositions and methods disclosed herein include, but are not limited to, the classes of disease: central

nervous system (CNS) disorders, peripheral nervous system (PNS) disorders, trauma-related disorders (including trauma to the head, the spine, and/or the PNS), genetic disorders, metabolic and/or endocrine related disorders (e.g., peripheral neuropathy in diabetes), toxin-related disorders (e.g., peripheral neuropathy induced by toxins (including chemotherapeutic agents)), inflammatory disease, exposure to excess vitamin, vitamin deficiency, and cardiovascular-related disorders (e.g., stroke). Examples of these classes include, but are not limited to, the following diseases and/or causes of disease: Huntington's disease, Alzheimer's disease, Parkinson's disease, Amyotrophic lateral sclerosis (ALS), axonal abnormalities (e.g., Wallerian degeneration), age-related neurodegeneration (including, for example, dementia), dementia pugilistica (or so called 'punch drunk syndrome'), shaken baby syndrome, spinal cord injuries (including injuries attributable to stretching, bruising, applying pressure, severing, and laceration), peripheral neuropathy disease or trauma, Friedreich's ataxia, Charcot-Marie-Tooth syndrome, diabetic neuropathy, diabetes mellitus, chronic renal failure, porphyria, amyloidosis, liver failure, hypothyroidism, exposure to certain drugs/toxins (including, for example, vincristine, phenytoin, nitrofurantoin, isoniazid, ethyl alcohol, and/or chemotherapeutic agents, organic metals, heavy metals, fluoroquinolone drugs), excess intake of vitamin B6 (pyridoxine), Guillain-Barré syndrome, systemic lupus erythematosus, leprosy, Sjögren's syndrome, Lyme Disease, sarcoidosis, polyglutamine (so called polyQ) diseases, Kennedy disease, Spinocerebellar ataxia Types 1, 2, 3, 6, 7, and/or 17, non-polyglutamine diseases, vitamin (e.g., vitamin B12 (cyanocobalamin), vitamin A, vitamin E, vitamin B1 (thiamin)) deficiency, exposure to physical trauma (e.g., exposure to compression, pinching, cutting, projectile injuries (i.e. gunshot wound), shingles, malignant disease, HIV, radiation, and chemotherapy.

[0084] The disclosure includes treating subjects with or at risk of diabetic neuropathy with the compositions disclosed herein to target and thereby modulate (e.g., inhibit) SARM (e.g., SARM1) to reduce axonal and/or synaptic degradation in the subject. Diabetic neuropathies are a family of nerve disorders caused by diabetes. About 60 to 70 percent of people with diabetes have some form of neuropathy. The incidence of neuropathy correlates with duration of disease. The highest rates of neuropathy are among people who have had diabetes for at least 25 years. Diabetic neuropathies also appear to be more common in people who have problems controlling their blood glucose, also called blood sugar, as well as those with high levels of blood fat and blood pressure and those who are overweight. Symptoms of diabetic neuropathy can include pain, tingling, or numbness—loss of feeling—in the hands, arms, feet, and legs. Nerve problems can occur in every organ system, including the digestive tract, heart, and sex organs.

[0085] The disclosure includes treating subjects scheduled to undergo and/or undergoing chemotherapy with the compositions disclosed herein to target and thereby modulate (e.g., inhibit) SARM (e.g., SARM1) to reduce axonal and/or synaptic degradation in the subject.

[0086] Subject Selection

[0087] The present disclosure includes selecting a subject for treatment, e.g., a subject with or at risk of a neurological disorder that manifests and/or includes axonal and/or synaptic degradation (e.g., Wallerian degeneration), e.g., a disorder

selected from the exemplary list provided above, and administering to the selected subject an effective amount of a composition disclosed herein.

[0088] The term "subject" is used throughout the specification to describe an animal, human or non-human, to whom treatment according to the methods of the present invention is provided. Veterinary and non-veterinary applications are contemplated. Subject selection can include diagnosis and/or referral by a physician or other qualified medical profession and self-referral by the subject to be treated. In some instances, methods can include selecting a subject with one or more of the classes of disease disclosed above. Alternatively or in addition, methods can include selecting a subject with one or more of the diseases disclosed above, or selecting a subject that has been exposed to a medical event, an environmental condition or factor, and/or a toxin known to be associated with an increased risk of or development of neurodegenerative disease.

[0089] For example, in some instances, methods can include selecting a subject at risk of diabetic neuropathy (e.g., a subject with diabetes mellitus) or a subject with diabetic neuropathy. Methods can also include selecting a subject scheduled to undergo and/or undergoing chemotherapy or treatment with a toxin associated with neurodegeneration. In some embodiments, the subject is in an early stage of disease, e.g., does not have advanced disease associated with complete neuronal death.

[0090] In some embodiments, the compositions and methods described herein do not include treatment of a subject with neurodegenerative disease attributable to oxygen and/or glucose deprivation (e.g., stroke) or Parkinson's disease. For example, selecting a subject can include, where appropriate, excluding subjects with neurodegenerative disease attributable to oxygen and/or glucose deprivation (e.g., stroke) or Parkinson's disease. For instance, selecting a subject can include selecting a subject with a neurodegenerative disease and excluding the selected subject if their neurodegenerative disease is associated with stroke or Parkinson's disease.

[0091] Treatment

[0092] Treatment can include administration of an effective amount of one or more of the compositions disclosed herein to target and thereby modulate (e.g., inhibit) SARM in a neuron (including in the neuronal cell body), in an axon, in a synapse, and/or in a dendrite. Compositions can be administered by any means that results in inhibition of SARM in a neuron (including in the neuronal cell body), in an axon, in a synapse, and/or in a dendrite. For example, compositions can be administered systemically and/or locally. Systemic administration can include use of compositions that target neurons in the CNS and/or PNS. Local administration can include administration of compositions to a defined region of the CNS and/or PNS, including, but not limited to, an injury site.

[0093] Frequency of administration can include once, twice, or more daily administration, for one or more days, and/or for a time that results in treatment of the subject's disease. In some instances, treatment can commence in a subject without neurodegenerative disease or that is at risk for neurodegenerative disease (e.g., in a subject with diabetes but without diabetic neuropathy, and/or in a subject scheduled to be exposed to an agent associated with the onset and/or development of neurodegeneration (e.g., chemotherapy), and/or in a subject that has experienced trauma of the CNS and/or PNS but that does not present symptoms of neurodegenerative disease (e.g., a subject with a head or PNS injury)). Alterna-

tively or in addition, treatment can commence in a subject with neurodegenerative disease. Treatment can include treating a subject without neurodegenerative disease or at risk for neurodegenerative disease, continuing to treat the subject following the onset of neurodegenerative disease, and/or treating a subject that previously had neurodegenerative disease.

[0094] Screening Methods

[0095] Also included are methods for selecting or identifying compositions, compounds, or agents that modulate (e.g., inhibit) SARM expression and/or activity, for use in the treatment of a neurological disorder that manifests and/or includes axonal and/or synaptic degradation (e.g., Wallerian degeneration), e.g., a disorder selected from the exemplary list provided above. Exemplary compositions can include compositions that interact (e.g., specifically interact) with SARM DNA, mRNA, and/or protein to thereby modulate (e.g., inhibit) SARM mRNA and/or protein expression and/or function. Methods include, for example, screening for candidate compounds using one or more of: in silico, in vitro and/or in culture (e.g., using high-throughput screening methods); and/or animal models (e.g., to test/verify candidate compounds as compounds that inhibit SARM). Compounds can also be evaluated in clinical trial, e.g., for use in human subjects. Techniques for performing such screening methods are known in the art and/or are described herein.

[0096] Compounds screened can include, but are not limited to, small molecules, inhibitory nucleic acids, antibodies, and inhibitory peptides. For example, commercial libraries of compounds (e.g., small molecules) can be screened using in vitro high-throughput screening methods. Such libraries include libraries containing compounds (e.g., small molecules) previously approved for use in human subjects (e.g., approved by the Federal Drug Administration).

[0097] In silico methods can be used to model the structure of SARM and to predict, model, select, and/or design compounds that interact with SARM or SARM domains (e.g., the SARM a helical domain, the SAM domain, and/or the TIR domain). In vitro methods can include biomolecular (e.g., protein) interaction methods (e.g., using BIARCORE), Fluorescence resonance energy transfer (FRET) in which a SARM binding molecule is used, and/or cellular or genetic reporter assays (e.g., luciferase or fluorescent protein based reporter assays).

[0098] Interaction methods can be used to assess the interaction of SARM with a compound or a candidate compound directly or indirectly via competition assay (e.g., wherein a compound or candidate compound competes with a SARM binding partner for SARM binding. In such assays, a decrease in binding of the SARM binding partner to SARM indicates that the compound or the candidate compound interacts with SARM). Such assays can be done in vitro or in cultured cells.

[0099] Genetic reporter assays are generally performed in cultured cells. Such assays can be used to screen for compounds that interfere with SARM expression and/or activity directly (e.g., by interaction with SARM) or indirectly (e.g., by interaction with SARM signaling). Useful genetic reporters can include, e.g., SARM (e.g., genetic reporters that include the SARM promoter or a portion thereof operably linked to a genetic reporter protein) and genes that are modulated by SARM (e.g., genetic reporters that include a promoter or portion thereof of a gene that is transcriptionally modulated by SARM). Suitable genes can be up-regulated or down-regulated by SARM. Compounds useful herein can

reduce the activity of a gene that is up-regulated by SARM in the absence of the compound. Cell culture methods can also include contacting a neuron with a candidate compound, injuring the neuron by axotomy, and assessing axonal and/or synaptic degradation in the neuron post axotomy. Compounds useful herein can reduce axonal and/or synaptic degradation in the neuron post axotomy.

[0100] Animal models can be used to assess candidate compounds, e.g., following their identification in silico and/or in vitro. For example, candidate compounds can be administered to an animal that has neurodegenerative disease to determine whether the candidate compound decreases one or more of: axonal and/or synaptic degradation; and/or reduce one or more symptoms of the disease; and/or reduces disease in the animal model, e.g., relative to disease in the animal in the absence of the candidate compound. Candidate compounds that reduce axonal and/or synaptic degradation; reduce one or more symptoms of the disease; and/or reduce disease in the animal model disease are compound that can be used herein. Various animal models are suitable for use in the screening methods disclosed here. For example, ALS mice and HD mice (DiFiglia et al, PNAS, 104(43):17204-9, 2007) can be used.

EXAMPLES

[0101] The invention is further described in the following examples, which do not limit the scope of the invention described in the claims.

Experimental Methods

[0102] Unless otherwise noted, the following methods were used in the Examples set forth below.

[0103] *Drosophila* Stocks, Transgenics, and Injury Protocol

[0104] The following *Drosophila* strains were used in this study: OR22a-Gal4; dMP2-Gal4 (Miguel-Aliaga and Thor, Development 131, 6093 (2004)); pUAST-mCD8::GFP; pUAST-nSynaptobrevin::GFP; 201y-Gal4; FRT2A/FRT82B; GMR-hid; Ubi-GFP::nls; FRT2A, tub-Gal80; ey-flp; usp² (Tp(3;1)KA21); Ect4-Gal4 (*Drosophila* Genetic Resource Center); and the 3(L) Deficiency Kit (all from Bloomington Stock Center unless noted). Mutants listed in Table 1 are all from Bloomington Stock Center or generous gifts from: E. Baehrecke; E. Arama; R. Tanguay; M. Guo; N. Tapon; and K. McCall. Lethal mutants were recombined onto a chromosome harboring a flippase recognition target (FRT) sequence and screened using MARCM clonal analysis with ey-flp. To establish mutant stocks for screening, we used the mutagen ethyl methane sulfonate (EMS) and established 2000 individual third chromosome F₂ mutant stocks containing FRT sites on both chromosomal arms (2A and 82B). Antennal injury was induced using a modification of a previously described protocol (MacDonald et al., Neuron 50, 869 (Jun. 15, 2006)). Adult flies were aged for 7 days at 25° C. after ablating the right third antennal segment only. Both antennae were ablated for synaptic preservation studies, as ORNs from each antenna synapse on both glomeruli. Injured flies were aged at 25° C. for the indicated time (7, 30, or 50 days) before dissecting and fixing the brain. Axonal integrity was scored as previously described (MacDonald et al., Neuron 50, 869 (Jun. 15, 2006)); Avery et al., J Cell Biol 184, 501 (Feb. 23, 2009)).

[0105] *Drosophila* Immunohistochemistry

[0106] Eye-imaginal discs from third instar larvae were dissected and TUNEL stained using In Situ Cell Death Detection Kit (Roche) as previously described (Klein, *Methods Mol Biol* 420, 253 (2008)). Embryos expressing dMP2-Gal4, UAS-mCD8::GFP were fixed as previously described (Miguel-Aliaga and Thor, *Development* 131, 6093 (December, 2004)). 1st instar larvae expressing dMP2-Gal4, UAS-mCD8::GFP were imaged live. Whole brains from either pre-pupae or pupae 18 hrs APF were dissected and staining with anti-FasII as described (Lee and Luo, *Trends Neurosci* 24, 251 (2001)). Embryos from yw or mutant stocks were fixed and staining with anti-FasII as previously described. Fas II antibody was used at a 1:10 dilution (Developmental Studies Hybridoma Bank). For dsarm rescue experiments, 22aGal4 was recombined with UAS-dsarm using standard fly techniques, and MARCM clones were generated using a line containing ey-flp, UAS-mCD8::GFP. Tdc-Gal4 neurons were imaged using a live fillet preparation (Ataman et al., *Neuron* 57, 705 (Mar. 13, 2008)). Secondary antibodies were obtained from Jackson Immunolabs and used at 1:200.

[0107] *Drosophila* Confocal Microscopy

[0108] Samples were mounted in Vectashield antifade reagent and viewed on a III Everest Spinning disk confocal microscope. The entire antennal lobe was imaged in 0.27 μ m steps for each sample for scoring axonal integrity. TUNEL-stained eye-imaginal discs were imaged on a Zeiss LSM5 Pascal confocal microscope.

[0109] *Drosophila* in situ

[0110] Standard methods were used for collection, fixation, and immunohistochemistry of *Drosophila* yw animals. dSARM cDNA corresponding to exon 5 in dsarm transcript RD was PCR-cloned into pCRII (Invitrogen). Digoxigenin-labeled RNA probes were generated according to the manufacturer's instructions (Roche). RNA in situ hybridization to embryos was carried out as described previously (Broadus et al., *Nature* 391, 792 (Feb. 19, 1998)). Third-instar larvae were decapitated in 1 \times PBS and fixed in 9% formaldehyde in PBS for 45 mins. Larval heads were hybridized in hybridization buffer (50% formamide, 5 \times SSC, 5 \times Denhardtts, 250 μ g/ml yeast tRNA, 500 μ g/ml herring sperm DNA, 50 μ g/ml heparin, 2.5 mM EDTA, and 0.1% Tween-20). Adult heads were decapitated on CO₂ and transferred to plastic embedding molds containing Tissue-Tek OCT. The samples were frozen on dry ice, and 15 μ m frozen sections were processed for in situ hybridization as previously described (Vosshall et al., *Cell* 96, 725 (Mar. 5, 1999)), with digoxigenin-labeled riboprobes and detected with TSA-Plus Fluorescein System (Perkin Elmer). Anti-digoxigenin-POD was diluted 1:500 (Roche).

[0111] Antibodies and Reagents for Mammalian Studies

[0112] Antibodies used in this study were: mouse monoclonal anti-Tau-1 (clone PC1C6, #MAB3420), and rabbit anti-neurofilament-M (#AB 1987) from Millipore; rabbit monoclonal anti- β -tubulin class III (#MRB-435P), and rabbit anti- α -internexin (#PRB-572C) from Covance; mouse monoclonal anti- β -actin (clone AC-15, #A5441) from Sigma; rat monoclonal anti-CD11b (clone M1/70.15, #MCA74EL) from AbD Serotec; rabbit anti-synaptophysin (#08-0130) from Invitrogen. Monoclonal neutralizing antibody against mouse NGF was previously described (Nikolaev et al., *Nature* 457, 981 (Feb. 19, 2009)). Secondary detecting antibodies conjugated with indicated Alexa dyes, and Alexa-594 conjugated α -bungarotoxin were from Invitrogen. Goat

serum, donkey serum, and horseradish-peroxidase conjugated donkey anti-rabbit IgG and donkey anti-mouse IgG were from Jackson ImmunoResearch. All other chemicals were from Sigma unless otherwise specified.

[0113] Mouse Surgery and Immunohistochemistry

[0114] All surgical and experimental procedures in mice were performed in compliance with the protocols approved by the Institutional Animal Care and Use Committee of The Rockefeller University, Cornell Weill Medical College, and The University of Massachusetts Medical School. Mice were anesthetized with isoflurane, and the skin on their right hind limb was shaved and prepared with iodine and alcohol. An incision was made between the knee and the hip joint, and the gluteal muscles were separated carefully with a pair of forceps. The sciatic nerve was transected as close to the thigh with a pair of sterile surgical scissors, and 1- to 2-mm of nerve segment was removed to prevent the regeneration of axons into the distal stump. The gluteal muscles were then brought back into their original anatomical position, and the overlying skin was re-approximated by surgical staples or sutures.

[0115] For light microscopy, the animals were euthanized at indicated time points post-surgery and nerve segments 3-6 mm distal to the lesion fixed with 4% paraformaldehyde and 2.5% glutaraldehyde in 0.1 M PBS, pH 7.4 (72 h at 4 $^{\circ}$ C.). After an extensive wash in 0.1 M PBS, 2 h of postfixation (1% osmium tetroxide) and dehydration in graded ethanol and propylene oxide, nerve segments were embedded in Durcupan resin (Fluka Chemie). After polymerization for 48 h at 60 $^{\circ}$ C., transverse semithin sections (0.5 μ m) were cut on a Leica ultramicrotome, stained with toluidine blue and photomicrographed. To quantify survival, 500 randomly chosen axons were counted. Survival criteria were normal myelin sheaths, uniform axoplasm and intact, unswollen mitochondria. A two-tailed one sample t-test was performed using GraphPad Prism 5.

[0116] For the biochemical analysis of sciatic nerves, the animals were euthanized at indicated time points post-surgery. A 10-mm segment of the nerve distal to the transection site was harvested, and immediately homogenized in 200 μ l Urea/SDS buffer [50 mM Tris-Cl (pH 6.8), 8.0 M urea, 10% (w/v) SDS, 10 mM sodium EDTA, and 50 mM DTT]. The nerve samples from two Sarm1 +/- or Sarm1 -/- mice were processed for each time point. After heating at 95 $^{\circ}$ C. for 10 min, 10- μ l aliquot of each nerve homogenate was subjected to 4-15% gradient Tris-glycine SDS-PAGE (Bio-Rad), and transferred to Immobilon-P PVDF membranes (Millipore) for immunoblot analysis. The membranes were immunoblotted with the indicated primary antibodies, and then the corresponding secondary antibodies in PBS/Tween-20. The bound antibodies were visualized by SuperSignal chemiluminescence reagents (Pierce). All membranes were exposed to Phoenix Blue X-ray film for 5 to 10 sec.

[0117] For immunohistochemistry, the mice were lethally anesthetized at the indicated time points post-surgery, and transcardially perfused with 4% paraformaldehyde/PBS. The sciatic nerves distal to the transection site was dissected, and post-fixed in 4% paraformaldehyde/PBS at 4 $^{\circ}$ C. overnight. After washing three times in PBS, the nerves were cryoprotected in 30% (w/v) sucrose/PBS at 4 $^{\circ}$ C. overnight, and then frozen in the 2:1 mixture of 30% sucrose/PBS:OCT (Tissue Tek) for 12- μ m longitudinal cryosections. The nerves were permeabilized in 0.5% Triton X-100 /PBS for 1 hour, and blocked in 0.5% Triton X-100/PBS containing 2% bovine serum albumin, and 4% goat serum at 4 $^{\circ}$ C. overnight. Immu-

nohistochemistry was carried out with either rabbit anti-neurofilament-M (1:500) or rat anti-CD11b (1:500) in the same blocking buffer at 4° C. overnight, followed by washing for 1 hour in 0.5% Triton X-100/PBS three times. The sections were then labeled with the corresponding Alexa-488 or Alexa-568 conjugated secondary antibodies for 2 hours, washed in PBS, and mounted in fluoromount-G. Images were taken at 2-mm distal to the transection sites, and 3 nonadjacent sections of each nerve sample were examined. Four (neurofilament-M axons) or three (CD11b macrophages/monocytes) mice of Sarm1 +/- or Sarm1 -/- were included per time point.

[0118] To examine denervation at neuromuscular junctions, the tibialis anterior muscles were dissected from perfused animals, and post-fixed in 1% paraformaldehyde/PBS at 4° C. overnight. After washing three times in PBS, muscles were cryoprotected in 30% sucrose/PBS at 4° C. overnight, and embedded in OCT for 80-um longitudinal cryosections. The tissues were permeabilized in 0.5% Triton X-100/PBS for 1 hour, and blocked in 1% Triton X-100/PBS containing 4% bovine serum albumin, and 4% donkey serum at 4° C. overnight. To label axons and neuromuscular junctions, muscles were stained with rabbit anti-neurofilament-M (1:500) and rabbit anti-synaptophysin (1:5) in the same blocking buffer at 4° C. for at least 24 hours. After washing for 1 hour in 0.5% Triton X-100/PBS three times, the muscles were incubated with Alexa-647 conjugated donkey anti-rabbit antibody (1:500) and Alexa-594 conjugated a-bungarotoxin (1:1000) overnight. After washing in PBS for 4 hours, sections were mounted in fluoromount-G, and imaged by LSM 510 laser scanning confocal microscope. To analyze presynaptic structures, maximum-intensity projections of z-stack images from 6 to 8 nonadjacent sections of each muscle sample were generated by AutoQuant X. Partial or full denervation was determined as the postsynaptic AChR sites not apposed by the presynaptic marker (colored in green for better visualization). About 100 neuromuscular junctions were examined for each muscle, and four Sarm1 +/- or Sarm1 -/- mice were included per time point.

Example 1

Identification of Genes Involved in Axonal Degradation

[0119] The *Drosophila* olfactory system is a model system for Wallerian degeneration. To determine whether Wallerian degeneration might be related to previously described cell destruction programs, a comprehensive screen of existing mutants and dominant negative constructs was performed for *Drosophila* genes affecting apoptosis, autophagy, or other defined cell degradative pathways, but these failed to suppress Wallerian degeneration in vivo at any level (Table 1).

TABLE 1

Mutations of known cell death and degeneration genes in <i>Drosophila</i> that do not block Wallerian degeneration		
Gene	Mutant Allele	Allele Type
ask1/pk92B	DN	OE
atg1	Δ3D	LOF
atg1	KQ #5B	OE of DN
atg1	68	OE of DN
atg1	EP3009	LOF

TABLE 1-continued

Mutations of known cell death and degeneration genes in <i>Drosophila</i> that do not block Wallerian degeneration		
Gene	Mutant Allele	Allele Type
atg1	KG03098	LOF
atg1	EP3348	LOF
atg2	EP3697	LOF
atg6	0.00096	LOF
atg7	d77	LOF
atg7	d14	LOF
atg18	KG03098	LOF
bsk/Jnk	DN	OE
bsk/Jnk	flp147E	LOF
buffy	H37	LOF
calcineurin A1	ED6346	DEF
calcineurin A1	BSC749	DEF
calx	UAS	OE
CaMKII	UAS	OE of DN
cullin-3	mds1	LOF
cullin-3	UAS	OE
cyt-c d	bin1	LOF
damm	f02209	LOF
dark	CD4	hypomorph
dark	CD8	hypomorph
debcl	E36	LOF
debcl	W105	truncated 5'
dIAP/thread	th1	LOF
dIAP/thread	UAS	OE
dIAP2	G2326	OE
dredd	B118	Null
dronc	CG	OE of DN
dronc	51	LOF
drp1	KG03815	LOF
dunce	1	Null
hsp22	EP(3)3247	OE
ik2	KALA	OE of DN
imd	1	Null
mstprox/toll-3	Exel 6146	Def
omi/htra2	UAS	OE
omi/htra2	Δ07	LOF
p35	UAS	OE
pmm	UAS	OE
puckered	UAS	OE
roc1b	dc3	LOF
sod1	UAS	OE
strica	4	Null
toll-6	ex13	Null
toll-7	g1.1	Null
tollo	59	Null
tor	TED	UAS of DN

All mutants or misexpression constructs were crossed into a background where a subset of ORNs were labeled with GFP (22a-Gal4, UAS-mCD8::GFP). ORN axons were severed, and degeneration was scored 5 days after axotomy.

LOF = reported amorphic loss of function allele;

OE = overexpression construct (under UAS-promoter control);

DN = dominant negative;

FL = full length of unmutagenized gene.

n ≥ 10 antennal lobes for all.

[0120] To identify new genes required to promote axon auto-destruction an F₂ forward genetic screen was performed in *Drosophila* for mutants that exhibited survival of axons after axotomy (FIG. 5). Because genes required for Wallerian degeneration may cause lethality when mutated, the screen was designed to allow for the isolation of essential and non-essential genes by characterization of both viable and lethal mutants through MARCM clonal analysis (Lee and Luo, Trends Neurosci 24, 251-254 (2001)).

[0121] A third chromosome line harboring flipase recombination target (FRT) sites, FRT2A, FRT82B, at the base of both arms of chromosome 3 was used. Methods started with a third chromosome isogenized strain where a subset of olfactory receptor neuron (ORN) axons were labeled with mem-

brane tethered GFP (OR22a-Gal4, UAS-mCD8-GFP), mutagenized with EMS, and established 2500 individual mutant F₂ stocks. If mutant lines were homozygous viable for the third chromosome, unilateral axotomy was induced in homozygotes by ablating the right antenna and assayed. Axonal integrity was assessed one week later via unilateral ablation of antennae. If mutant lines contained lethal mutations on chromosome 3, MARCM clones (Lee and Luo, Trends Neurosci 24, 251-254 (2001)) were generated in ORNs individually for 3R and 3L. Axotomies were performed and analyzed as described for the viable lines.

[0122] Axotomy in wild type flies resulted in severed axons being completely cleared from the right antennal lobe within 1 week after injury (FIG. 1A—wild type). In contrast, certain mutants showed normal axon function post-axotomy. Specifically, four lethal lines, 1(3)896, 1(3)4621, 1(3)4705, and 1(3)7152, were identified in which severed axons generated by MARCM remained intact 1 week after axotomy (FIG. 1A). While the number of uninjured axons was slightly reduced in each mutant, 100% of GFP-labeled axons exhibited long-term preservation after injury (Table 2, below). Remarkably, mutant axons remained fully intact 30 days after injury (FIG. 1B) and a significant but reduced number remained morphologically intact even 50 days after injury (FIG. 1C). 1(3)896, 1(3)4621, and 1(3)4705 therefore provide axonal preservation that rivals that of Wlds in *Drosophila*, and which lasts essentially for the lifespan of the fly. As described in more detail below, intact axons were also observed 30 days and 50 days post axotomy (FIGS. 1B and 1C). Neuroprotection in these mutants extended to synapses: synaptobrevin punctae localized to synaptic terminals even 30 days after axotomy (see below and FIGS. 1D and 1E). In each of these mutants OR22a+ axonal morphology, pathfinding, and innervation of antennal lobe glomeruli appeared normal, suggesting that none of these mutants grossly affected ORN development. All four mutants were homozygous lethal, and failed to complement one another for lethality. Thus each appears to represent an independently isolated lethal mutation in the same gene.

[0123] Previous work (9, 10, 12) and the present data argue that Wallerian degeneration is molecularly distinct from apoptosis and developmental neurite pruning. To determine whether 1(3)896 is broadly required for neuron pruning or apoptotic cell death, MARCM clones were examined in *Drosophila* mushroom body γ neurons, as these neurons undergo both dendritic and axonal pruning during metamorphosis (15). In both control and 1(3)896 animals, mushroom body γ neuron axons and dendrites were pruned normally (FIG. 1F). During normal early embryogenesis, dMP2 neurons are present in each segment, but by late embryogenesis, all but the posterior 3 pairs undergo developmentally-programmed apoptosis (16). dMP2 neurons were generated normally in 1(3)4621 animals, and the appropriate subset of neurons underwent apoptosis (FIG. 1G). Finally, the pro-apoptotic gene *hid* was expressed in the *Drosophila* visual system (17) to induce widespread apoptotic death in cells of the developing eye disc. The 1(3)896 mutant clones failed to suppress activation of cell death (FIGS. 1H and 1I).

Example 2

Validation of Axonal Protection for MARCM Clones

[0124] To determine the penetrance of axonal protection, MARCM clones were generated in the indicated mutant

strains. Axons labeled with OR22aGal4, UAS-mCD8::GFP were aged for 7 days after eclosion, followed by unilateral antennal ablation. Axonal integrity was scored 7 days after injury in both uninjured and injured glomeruli. $n \geq 10$ lobes for all. Data is presented in Table 2.

TABLE 2

Production of MARCM clones and persistence of severed axons in axon protective mutant backgrounds		
Mosaic chromosome	Number of Axons (uninjured)*	Number of Axons 7 days post axotomy*
Wild type	11.08 +/- 1.52	0
1(3)896	4.71 +/- 1.76	5.43 +/- 2.12
1(3)4621	7.44 +/- 0.66	6.13 +/- 0.74
1(3)4705	4.94 +/- 0.85	5.00 +/- 1.61

*Number of individual axon fibers identified in z-stacks from confocal imaging of entire antennal lobe.
N = >10.

[0125] As shown in Table 2, on average, control chromosomes led to the production of 11.08 ± 1.52 GFP-labeled axons in MARCM clones. In contrast, in 1(3)896, 1(3)4621, and 1(3)4705 backgrounds, 4.71 ± 1.76 , 7.44 ± 0.66 and 4.94 ± 0.85 GFP-labeled axons in MARCM clones were observed. The observed consistently reduced number of axons labeled in mutant background indicates that loss of the affected gene's function results in a growth disadvantage for ORNs compared to wild type cells (see the column entitled "uninjured"). However, the number of GFP-labeled axons that exhibit long term survival in each of the mutants is not significantly different from the number labeled prior to injury, indicating in each of these mutant backgrounds essentially 100% of axons were protected 1 week after injury.

Example 3

Duration of Axonal Protection

[0126] In *Drosophila* *Wld^S* expression is sufficient to protect severed axons for 30-40 days after axotomy, but beyond that time point axons degenerate (Avery et al., J. Cell. Biol., 184:501-513, 2009). Axonal integrity was assessed in the mutants described above at 30 and 50 days post axotomy.

[0127] As shown in FIGS. 1B-1C, in 1(3)896, 1(3)4705, 1(3)4621, and 1(3)7152 mutant clones axons remained fully intact 30 and 50 days post axotomy. Since *Wld^S*-mediated axon protection disappears by day 50, these mutants exhibit axon protective phenotypes that significantly exceed *Wld^S*. Moreover, the median lifespan of *Drosophila* is ~30 days, thus severed axons are protected in these mutants for essentially the entire lifespan of the fly.

Example 4

Characterization of MARCM Clones—Identification of dSARM

[0128] Two approaches were employed to identify the gene affected in 1(3)896, 1(2)4621, 1(3)4705, and 1(3)7152 mutants. First, lethality was mapped using small chromosomal deficiencies. By assaying for non-complementation it was possible to map the lethality to a single gene, *Ect4* (hereafter referred to as dSARM for *Drosophila* SARM), using an array of partially overlapping deficiencies in the 66B region of chromosome 3 (FIG. 2A).

[0129] In addition, next-generation sequencing technology was used to re-sequence the entire genome of each mutant (along with the unmutagenized control line) to an average read depth of 70× in order to identify novel mutations in open reading frames in genes on 3L, and more specifically, any gene mutated in all four mutant backgrounds (Table 3).

TABLE 3

Identification of dsarm through re-sequencing of mutant genomes			
	One mutant line (# of genes)	Any two mutant lines (maximum # of genes)	All three mutant lines (# of genes)
Unique coding variants; genome wide	92 (l(3)896) 997 (l(3)46210) 272 (l(3)4705)	166	6
Unique coding variants; chromosome 3L	34 (l(3)896) 132 (l(3)46210) 46 (l(3)4705)	8	3
+ nonsynonymous or splice site and heterozygous changes	17 (l(3)896) 66 (l(3)46210) 23 (l(3)4705)	2	1

The number of identified variants are indicated within and across mutant lines. Filtering strategy was as indicated above.

[0130] This approach identified a single gene affected in all of the mutants which resided in cytogenetic region 66B: ect4, which is referred to herein as dsarm (*Drosophila* sterile alpha and Armadillo motif). The dsarm gene encodes a protein with an Armadillo/HEAT (ARM) domain, two sterile alpha motifs (SAM), and a Toll/Interleukin-1 Receptor homology (TIR) domain. Each identified dsarm allele contained a unique premature stop codon in dsarm open reading frame (FIGS. 2B, 2C).

[0131] As illustrated in FIG. 2C, the 1(3)896, 1(2)4621, and 1(3)4705 mutants each contained a unique premature stop codon in dSARM. The predicted protein products from 1(3)896 and 1(2)4705 would be truncated prior to the ARM, SAM, and TIR domains; that from 1(2)4621 would be truncated early in the first SAM domain. 1(3)7152 is a point mutation in the first SAM domain (1986S). These observations confirm that the MARCM mutations are recessive and that three of the four alleles result in premature stop codons. Accordingly, the mutations are loss-of-function mutations.

[0132] To test this interpretation, dsarm was cloned for expression studies. The first 630-4828 nucleotides of the partial dsarm cDNA GH07037 (DGRC) was cloned into the pCashsp40-LacZ vector with BglII/XhoI. The remaining sequence was obtained by PCR amplifying a fragment from cDNA IP03452 (DGRC) using 5'ECT4-D NotI (atatatcg-gccgcaaacATGGGCAATCGTTTGAGCGGC; SEQ ID NO:7) and PM001 (CGTTAGAACGCGGCTACAAT; SEQ ID NO:8), then cut with NotI/BglII and ligated into the pCashsp40-LacZ vector. The resulting full length dsarm was then PCR amplified off the pCashsp40-LacZ vector using the above 5'ECT4-D NotI and 3' Ect4-D aa1610-1637 (agatactgagTTACCAAAATATCATGCGCCCG-GCATTGGGGGAGGTGGCCTTGA CAGAATGATGCCGAAAGTTCCTCGTCTCCATTTTCGTTGTTTTT-ATCAGCG AGCCGACCTTCTCATCG; SEQ ID NO:9), cut with NotI/XhoI, and ligated into pUAST vector (generating pUAST-dsarm). pUAST-dsarm::GFP was generated by cloning into the NotI/SpeI sites of pUAST-CT EGFP with PCR-amplification off the pUAST-dsarm construct using

5'ECT4-D NotI and 3' ECT4-D SpeI (gatcactagtC-CAAAATATCATGCGCCCGGCGATTGG; SEQ ID NO:10).

[0133] The results were consistent with the above interpretation; expression of full length dsarm cDNA using the post-mitotic OR22a-Gal4 driver in 1(3)896 mutant clones was sufficient to fully revert the suppression of axonal degeneration observed in dsarm mutants (FIG. 2D). In addition, both the lethality and suppression of Wallerian degeneration phenotypes were rescued in 1(3)896/1(3)4621 and 1(3)896/Df(3L)BSC795 trans-heterozygous animals with a BAC clone containing the dsarm gene. Together these data indicate that dsarm is necessary in post-mitotic neurons for axonal destruction after axotomy, and loss of dsarm function is sufficient to provide long-term preservation of severed axons.

[0134] Based on RNA in situ hybridizations to embryos, larval brains, and adult brains, RT-PCR from dissected neural tissues, and analysis of a dsarm-Gal4 driver line, dsarm appears to be widely expressed in the *Drosophila* nervous system. This observation suggests that dSarm is broadly required to promote Wallerian degeneration in the nervous system.

Example 5

Functional Characterization of dSARM

[0135] A number of cell degradative programs are engaged to dispose of neurons, or parts of neurons including apoptotic cell death pathways and axonal pruning or dendritic pruning programs (Raff et al., Science, 262:695-700, 1993; Luo and O'Leary, Annu Rev. Neurosci., 28:127-156, 2005). Wld^s does not block cell death or developmental axon pruning and, reciprocally, molecules that block apoptotic cell death do not block axon degeneration after injury (Simonin et al, Eur. J. Neurosci., 25:2269-2274, 2007; Hoopfer et al., Neuron, 50:883-895, 2006; Finn et al., J. Neurosci., 20:1333-1341, 2000).

[0136] To determine whether dSARM mutations were capable of affecting other types of neuronal degradation besides Wallerian degeneration, MARCM clones were generated in *Drosophila* mushroom body γ neurons using control and dSARM⁸⁹⁶ chromosomes.

[0137] MARCM clones were generated with wild type or dSARM⁸⁹⁶ chromosomes during larval stages using the 201Y-Gal4 driver, which labels mushroom body γ neurons. Dendritic and axonal pruning in the dorsal and medial bindles were scored at 0 and 18 hours after puparium formation (APF). As shown in FIG. 1F, in both control (wild type) and dSARM⁸⁹⁶ animals, γ neuron axons and dendrites were fully pruned by 18 hours after puparium formation. These data indicate that loss of dSARM function does not affect developmental neurite pruning.

[0138] The potential role of dSARM in naturally occurring and induced cell death during development was also examined. First, the dMP2-Gal4 driver was crossed into control and dSARM⁴⁶²¹ backgrounds. This marker allows for the unique identification of the dMP2 neurons which are initially generated in each embryonic segment, but later undergo cell death in all segments but A7-9 before the 1st instar larval stage (Miguel-Aliaga and Thor, Development, 131:6093-6105, 2004). As shown in FIG. 1G, dMP2 neurons were generated normally in both control and dSARM⁴⁶²¹ animals and the appropriate subsets underwent cell death prior to larval hatching. Further, the normal complement of dMP2 neurons were identified in stage 16 embryos, and all under-

went programmed cell death expect the 3 most posterior abdominal pairs by 1st instar larval stages.

[0139] To evaluate the role of dSARM in cell death, cell death was induced in the developing visual system using the GMR-hid approach (Grether et al., *Genes Dev.*, 9:1694-1708, 2005), and made clones of both control and dSARM⁸⁹⁶ chromosomes and assayed for any suppression of cell death (e.g. rescue of eye ablation).

[0140] As shown in FIG. 1H, it was found that dSARM mutations had no effect on the activation of cell death in the visual system by hid expression.

[0141] These data reveal that dSARM has no effect on the activation or execution of neurite pruning or apoptotic cell death.

[0142] In addition, our studies revealed axonal degeneration is not impacted by the loss of known autophagic or apoptotic genes, including the autophagy genes PTEN, TOR, Atg 1, 2, 6, 7, and 18; and the apoptosis genes Cyt C Diap1, Diap2, Debc1 Buffy, Dronc, Roc2, Gft, Cu13, Dark, and p35.

Example 6

Mammalian SARM1 Mediates Wallerian Degeneration

[0143] Wallerian degeneration was next assayed in null mutants for the mouse ortholog of dsarm, Sarm1. Five day cultures of superior cervical ganglia (SCG) were cultured from wild type, Sarm1^{-/-}, and Wld^S mice, severed axons, and axonal integrity scored over the next week. Similar experiments were conducted in dorsal root ganglion (DRG) and cortical neuron cultures.

[0144] SCG explants were dissected from 0-2 day old pups and cultured as previously described (Gilley and Coleman, *PLoS Biol* 8, e1000300 (2010)). Axons were allowed to extend for 5 days before separation from the cell body mass using a scalpel. The degeneration of the isolated axons was followed at different time points for 72 h after cut. Bright field images were acquired on a microscope (IX81; Olympus) coupled to a digital camera (U-TV 0.5XC; Olympus) using AnalySIS software (Soft Imaging Systems GmbH, Germany). Axonal protection was quantified as described (Gilley and Coleman, *PLoS Biol* 8, e1000300 (2010)). Typically an image of intact axons has a protection index (PI) value around 1. A PI around 0 occurs when axons detach from the dish. A two-way repeated measures analysis of variance (ANOVA) was used to show the difference in axonal protection between wild-type and Sarm1^{-/-}. For dissociated SCG cultures, cells were microinjected as previously described (Gilley and Coleman, *PLoS Biol* 8, e1000300 (January, 2010)) with 50 ng/μl of mito-tagRFP construct created by PCR amplification of the mitochondrial targeting sequence (aa 1-24) of *Mus musculus* cytochrome c oxidase subunit VIIIb (GenBank AK003116.1) and insertion into the MCS of the pTagRFP-N vector (Evrogen). 24 hours after microinjection cultures were immunostained using 0.3 μg/ml mouse monoclonal anti-SARM1 antibody (Chen et al., *J Cell Biol* 193, 769 (2011)) and Alexa-488 secondary antibody. Cultures were visualized on an Olympus FV1000 point scanning confocal microscope using a 60× 1.35NA apochromat objective.

[0145] For cortical neuron cultures, Campenot dividers (Tyler Research) were set up in poly-D-lysine/laminin-coated 2-well chamber culture slides. On DIV 0 (Day In Vitro 0), neocortices were dissected from six E16.5 Sarm1^{+/+} or Sarm1^{-/-} embryos, pooled, and dissociated in Hank's Balanced Salt Solution (without Ca²⁺ and Mg²⁺, Invitrogen) containing 0.05% (w/v) trypsin/EDTA at 37° C. for 10 min. After adding a final concentration of 10% (v/v) heat-inacti-

vated fetal bovine serum (HI-FBS), the tissues were spun down at 500 g for 3 min. The tissues were then suspended and triturated in Neurobasal/B-27 medium [Neurobasal medium supplemented with 2% (v/v) B-27, 2 mM glutamine, 100 U/ml penicillin, and 100 ug/ml streptomycin] containing 10% HI-FBS. The cells were plated in the cell-body compartment of Campenot dividers at a density of 2.5×10⁵ per well. To facilitate the axotomy later, Campenot dividers were removed after 6 hours, when the cells already attached to the slides. From DIV 3, half of the culture medium was replaced every other day by fresh Neurobasal/B-27 medium containing 5 μM 5'-flourouridine and 5 μM uridine to suppress the proliferation of non-neuronal cells. On DIV 10, the cultures were subjected to axotomy.

[0146] For the dorsal root ganglion (DRG) cultures, DRGs were dissected from four E13.5 Sarm1^{+/+} or Sarm1^{-/-} embryos on DIV 0. The explants from each embryo were individually plated in poly-D-lysine/laminin-coated 4-well chamber culture slides in F-12 /N-3 medium [Ham's F-12 medium supplemented with 40 mM glucose, 4% (v/v) N-3 supplement, and 50 ng/ml mouse NGF]. On DIV 1, the cultures were changed to fresh F-12/N-3 medium containing 1 μM cytosine β-D-arabinofuranoside to suppress the proliferation of non-neuronal cells. On DIV 3, the explants were subjected to either the axotomy, or the NGF deprivation with a final concentration of 50 ug/ml anti-NGF antibody.

[0147] To visualize the axons, the cultures were fixed in 4% paraformaldehyde (w/v)/phosphate-buffered saline (PBS) at room temperature for 30 min, followed by the permeabilization with 0.1% (v/v) Triton X-100/PBS for 30 min. The axons were then immunostained with the indicated primary antibodies in 0.1% Triton X-100/PBS containing 2% (w/v) bovine serum albumin, and 2% (v/v) goat serum at 4°C overnight, followed by the corresponding Alexa-488 or Alexa-568 conjugated secondary antibodies. To quantify axon degeneration, the images of distal axons were taken from 2 random fields per well, and 40 to 80 singly distinguishable axons in each field were examined, with any sign of fragmentation scored as degeneration. For each time point, 4 wells of Sarm1^{+/+} or Sarm1^{-/-} cortical neuron cultures, or the DRG explants from 4 embryos of Sarm1^{+/+} or Sarm1^{-/-}, were included.

[0148] Sarm1^{-/-} SCG explants exhibited robust protection from degeneration up to 72 hours after axotomy, similar to what is observed with Wld^S SCG neurons, while wild type axons degenerated within 8 hours (FIG. 3A,B). This robust protection was also seen in cultured Sarm1^{-/-} cortical neuron axons (FIG. 3C,D) and dorsal root ganglia (DRG) (FIG. 3E,F). Notably, Sarm1^{-/-} DRG explants were not protected from nerve growth factor (NGF) deprivation (FIG. 3G,H), a mouse model for developmental axon pruning (4, 15, 18, 19), suggesting that in mammals Sarm1 protection is specific to injury-induced axon degeneration. Thus Sarm1 loss of function robustly suppresses Wallerian degeneration in multiple types of mammalian axons in vitro. In addition, based on use of culture conditions that minimize the presence of satellite cells among the axons, the present data argue that Sarm1 is required cell autonomously for programmed axonal death.

[0149] To test whether Sarm1 is required in vivo for Wallerian degeneration, sciatic nerve lesions of the right hind limb were performed in Sarm1^{-/-} mice and their heterozygous littermate controls. Impressively, while Sarm1^{+/+} controls exhibited a dramatic breakdown of the axon and myelin sheath within 3 days of injury, 61.2% of lesioned Sarm1^{-/-} axons were protected from degeneration at least 14 days after injury (p=0.002) (FIG. 4A,E). Analysis of sciatic nerve ultrastructure revealed a remarkable structural preservation at 14

days after axotomy of the Schwann cell and myelin sheath, axonal neurofilaments, and axonal mitochondria (FIG. 4B; FIG. 6A). Western blots of sciatic nerve were performed and probed with antibodies to neurofilament-M (NF-M), α -Internexin, and β -tubulin class III (TUJI). While a dramatic breakdown of these proteins was observed in wild type nerves, they remained largely intact in *Sarm1*^{-/-} axons (FIG. 4D). In addition, preservation of the NF-M signal was observed by immunofluorescent staining of the nerve in *Sarm1* mutants (FIG. 6A).

[0150] Neuromuscular junctions were examined in tibialis anterior muscles after sciatic nerve transection. Synaptic integrity was scored by co-localization of presynaptic marker (NF-M/synaptophysin) with the post-synaptic acetylcholine receptor (AChR). In wild type animals, motor endplate denervation was complete by 2 days after axotomy. However in *Sarm1*^{-/-} animals, most synaptic terminals were partially innervated even at 6 days after injury (FIG. 4C,F). Macrophage/monocyte infiltration of lesioned nerves was suppressed in *Sarm1* knockout animals (FIG. 6B). Taken together, these results indicate that *Sarm1*^{-/-} mutations provide a dramatic preservation of sciatic nerves in vivo from initial axonal cytoskeletal breakdown to recruitment of macrophages for myelin clearance.

[0151] Finally, in vivo localization of dSarm and *Sarm1* was assayed. To determine the subcellular localization of dSarm, a GFP-tagged version of dSarm (UAS-dSarm-GFP) was generated and expressed via *tdc-Gal4* in larval motoneurons. dSarm-GFP localization was assayed in third instar larvae. Axons and cell bodies were identified by co-expression of UAS-mCD-mCherry. Expression of dSarm::GFP in larval neurons resulted in punctate localization in neuronal cell bodies, and broad localization to neurites. Similarly, immunostaining with anti-*Sarm1* antibodies of in vitro cultured mammalian neurons showed a broad, punctate pattern in neurites, and endogenous *Sarm1* did not show preferential localization with a mitochondrial marker.

References Cited

- [0152]** 1. A. Waller, *Philos. Trans. R. Soc. Lond. B Biol. Sci.* 140, 423 (1850).
[0153] 2. E. R. Lunn, V. H. Perry, M. C. Brown, H. Rosen, S. Gordon, *Eur J Neurosci* 1, 27 (1989).
[0154] 3. J. D. Glass, T. M. Brushart, E. B. George, J. W. Griffin, *J Neurocytol* 22, 311 (May, 1993).
[0155] 4. M. C. Raff, A. V. Whitmore, J. T. Finn, *Science* 296, 868 (May 3, 2002).
[0156] 5. M. P. Coleman, V. H. Perry, *Trends Neurosci* 25, 532 (October, 2002).
[0157] 6. T. G. Mack et al., *Nat Neurosci* 4, 1199 (December, 2001).
[0158] 7. M. P. Coleman, M. R. Freeman, *Annu Rev Neurosci* 33, 245 (2010).

- [0159]** 8. T. L. Deckwerth, E. M. Johnson, Jr., *Dev Biol* 165, 63 (September, 1994).
[0160] 9. J. T. Finn et al., *J Neurosci* 20, 1333 (Feb. 15, 2000).
[0161] 10. A. V. Whitmore, T. Lindsten, M. C. Raff, C. B. Thompson, *Cell Death Differ* 10, 260 (February, 2003).
[0162] 11. Q. Zhai et al., *Neuron* 39, 217 (Jul. 17, 2003).
[0163] 12. E. D. Hoopfer et al., *Neuron* 50, 883 (Jun. 15, 2006).
[0164] 13. B. R. Miller et al., *Nat Neurosci* 12, 387 (April, 2009).
[0165] 14. T. Lee, L. Luo, *Trends Neurosci* 24, 251 (May, 2001).
[0166] 15. L. Luo, D. D. O'Leary, *Annu Rev Neurosci* 28, 127 (2005).
[0167] 16. I. Miguel-Aliaga, S. Thor, *Development* 131, 6093 (December, 2004).
[0168] 17. M. E. Grether, J. M. Abrams, J. Agapite, K. White, H. Steller, *Genes Dev* 9, 1694 (Jul. 15, 1995).
[0169] 18. B. L. MacInnis, R. B. Campenot, *Mol Cell Neurosci* 28, 430 (March, 2005).
[0170] 19. R. R. Buss, W. Sun, R. W. Oppenheim, *Annu Rev Neurosci* 29, 1 (2006).
[0171] 20. M. Mink, B. Fogelgren, K. Olszewski, P. Maroy, K. Csiszar, *Genomics* 74, 234 (Jun. 1, 2001).
[0172] 21. Y. Kim et al., *J Exp Med* 204, 2063 (Sep. 3, 2007).
[0173] 22. C. F. Chuang, C. I. Bargmann, *Genes Dev* 19, 270 (Jan. 15, 2005).
[0174] 23. C. Chang, Y. W. Hsieh, B. J. Lesch, C. I. Bargmann, C. F. Chuang, *Development* 138, 3509 (August, 2011).
[0175] 24. E. B. George, J. D. Glass, J. W. Griffin, *J Neurosci* 15, 6445 (October, 1995).
[0176] 25. S. A. Barrientos et al., *J Neurosci* 31, 966 (Jan. 19, 2011).
[0177] 26. J. M. MacDonald et al., *Neuron* 50, 869 (Jun. 15, 2006).
[0178] 27. M. A. Avery, A. E. Sheehan, K. S. Kerr, J. Wang, M. R. Freeman, *J Cell Biol* 184, 501 (Feb. 23, 2009).
[0179] 28. T. Klein, *Methods Mol Biol* 420, 253 (2008).
[0180] 29. N. H. Patel, *Methods Cell Biol* 44, 445 (1994).
[0181] 30. A. Nikolaev, T. McLaughlin, D. D. O'Leary, M. Tessier-Lavigne, *Nature* 457, 981 (Feb. 19, 2009).
[0182] 31. J. Gilley, M. P. Coleman, *PLoS Biol* 8, e1000300 (January, 2010).

OTHER EMBODIMENTS

[0183] It is to be understood that while the invention has been described in conjunction with the detailed description thereof, the foregoing description is intended to illustrate and not limit the scope of the invention, which is defined by the scope of the appended claims. Other aspects, advantages, and modifications are within the scope of the following claims.

SEQUENCE LISTING

```
<160> NUMBER OF SEQ ID NOS: 10

<210> SEQ ID NO 1
<211> LENGTH: 7001
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<300> PUBLICATION INFORMATION:
<308> DATABASE ACCESSION NUMBER: GenBank Accession No. NM_015077
```

-continued

<400> SEQUENCE: 1

cctccagggc ggggatgtcc cccgcggccc 60
cgccccatg gtctctcgc cgtggccccg cctccagggc ggggatgtcc cccgcggccc 60
cgccccatg gtctctcgc cgtctctctc cgcctacaag ctgtgtcgtc tcttcgccat 120
gtcgggcccc cggccggggc cggagcggct ggcggtgccct gggccagatg ggggcggtgg 180
cacgggcccc tgggtggctg cgggtggccg cgggccccgc gaagtgtcgc cgggggcagg 240
cacggaggtg caggacggcc tggagcggc gctgccggag ctgcagcagg ccttgtccgc 300
gctgaagcag gcgggcccgc cgcgggcccgt gggcggccgc ctggccgagg tcttccaact 360
ggtggaggag gcctggctgc tgcggcccgt gggcggcggc gttagcccagg gtctgtgcga 420
cgccatccgc ctgcagggc gcctcagacc gctgttgcgg ctgctgcagg cgcgggagtt 480
ggagacgcgt gtgcaggccc cgcgcctgct ggagcagatc ctggtggctg agaaccgaga 540
ccgctggggc cgcattgggc tgggctgat cctgaacctg gcgaaggaaac gccaaccctg 600
agagctggcg cggagcgtgg caggcatctt ggagcagatg tcaagcatt cggaggagac 660
atgccagagg ctggtggcgg cggcggcccct ggagcgggtg ctgtattggt gccgccgcac 720
ggaccccgcg ctgctcggcc actgcggcgt ggcgctgggc aactgcgcgc tgcacggggg 780
ccagggcggg cagcagcga tggtagagaa gcgcgcagcc gagggtctct tcccgctcgc 840
cttctccaag gaggacgagc tgcttcggct gcacgcctgc ctgcagtag cgggtttggc 900
gactaacaag gaggtggagc gcgaggtgga gcgctcgggc acgctggcgc tegtggagcc 960
gcttgtggcc tgcctggacc ctggccgctt cgcggcgtgt ctggtggacg ccagcagcac 1020
aagccagggc cgcgggcccc acgacctgca gcgcctcgtg ccgctgtcgc actctaaccg 1080
cttggaggcg cagtgcatcg gggctttcta cctctgcgcc gaggctgcca tcaagagcct 1140
gcaaggcaag accaagtggt tcagcagcat cggcggccatc cagagcctga aacgcctggt 1200
ttctactct accaatggca ctaagtcggc gctggccaag cgcgcgctgc gcctgtggg 1260
cgaggaggtg ccacggcccc tccctgccctc cgtgccagc tggaggagg cggaggttca 1320
gacgtggctg cagcagatcg gtttctccaa gtactgcgag agcttccggg agcagcaggt 1380
ggatggcgac ctgcttctgc ggctcagga ggaggaactc cagaccgacc tgggcatgaa 1440
atcgggcate acccgaaga ggttctttag ggagctcagc gagctcaaga ccttcgcca 1500
ctattctacg tgcagccgca gcaacctggc ggactggctg ggcagcctgg acccgctct 1560
ccgccagtac acctacggcc tggtcagctg cggcctggac cgtccctgc tgcaccgct 1620
gtctgagcag cagctgctgg aagactgcgg catccacctg ggcgtgcacc gcgcccgc 1680
cctcacggcg gccagagaaa tgctaacctc cccgctgccc tgtactggtg gcaaacccag 1740
tggggacact ccagatgtct tcatcagcta ccgcccgaac tcaggttccc agctggccag 1800
tctcctgaag gtgcacctgc agctgcctgg cttcagtgct ttcattgatg tggagaagct 1860
ggaagcagcg aagttcagag acaaacctcat ccagagtgc atgggtgccc gcaactttgt 1920
gttgggtgcta tcacctggag cactggacaa gtgcatgcaa gaccatgact gcaaggattg 1980
ggtgcataag gagattgtga ctgctttaag ctgcggcaag aacattgtgc ccatcattga 2040
tggtctcgag tggcctgagc cccaggtcct gcctgaggac atgcaggtg tgettacttt 2100
caacggtatc aagtggtccc acgaatacca ggaggccacc attgagaaga tcattccgctt 2160
cctgcagggc cgtccctccc gggactcact tgcaggtct gacaccagtt tggaggggtg 2220
tgcacccatg ggtccaacct aaccagtcct cagttcccca gcctgtctgt gacttccatt 2280

-continued

tccatcgtcc	tttctgaagg	aacagctcct	gaaaccagtc	tccttgggct	gagacaacct	2340
gggctcttct	taggaaatgg	ctctcctccc	cctgtcccc	cacctcatg	gcccacctcc	2400
aaccacttt	cctcagtatc	tggagaggga	agggaagtca	ggcttgggca	cgggaggtta	2460
gaaactcccc	aggcctgccc	attgggttgt	ctgtctccgt	catggggagg	gtcctgtctc	2520
agttctggag	aaactggagt	tgggttgggg	gtggttctgc	attccttctc	cctgctgata	2580
gcagtcagct	tgaggaggat	gaaggaaagg	agcctcagac	aggaattaag	gcaatgccc	2640
ggcgggctg	ggcactgtat	tctgagcaaa	ggcctgggccc	caggagccag	ccagggatga	2700
gtgccatcat	ggctctccac	tcagactgtg	cctggcccc	gcacttaca	cttctgccc	2760
ctctgtggcc	ttgcctgta	atcactcagt	gcccttagct	agcctgacta	agtcccagat	2820
ccccacagc	ttcctcggt	gtggtatctt	ttgccacatc	cagggcgagg	ggtgaggcaa	2880
accagccctc	cctctgactt	ccttgtcact	gcagccagct	ttgctgact	tgctggtgca	2940
caggagcctc	ctgtttgggc	ctgggtctgg	gcattggggag	gccgtgcctc	aaagcccacc	3000
ctaccccatg	ccttgggtgt	gtgcctcagg	ctccttctg	gtctggccca	gctggcttcc	3060
ccagccctc	agccatccag	ggctacccc	tgttactca	gggaccaggc	agccccatg	3120
gcagtaaaag	cagcctagac	agaacctgca	gctctgtgga	aagaggcaaa	gtcctgaaaa	3180
ggcaaagggt	tgctacttag	ggcagcttct	ccaactttaa	catgcatcca	agtccactgg	3240
gaatgtgtt	aaaatcagga	gatctggggt	ggggcctagg	actctgcatt	tcttacagat	3300
tcccagggtg	gctgatgctg	gtggttaagg	gtagcaaatc	tctaaagcac	gaagccctca	3360
caaatctttg	ccatttccca	aacactccgc	tccatggtct	ccagtcacca	gagcaactct	3420
acctggtatt	atcatcccca	ttttacagat	aatgacactg	aggctcagaa	aggttgagga	3480
taagcccact	ttcctgtcat	tagtggcagc	cccagatcca	gacctaggcc	tcctggcacc	3540
cagtccactg	gcagtggaat	tgctttcctg	agaatcattc	tgaggctggg	ctattgcttc	3600
tccttgcctt	caaagaatct	agcagcgggg	gataggattt	tgcaacaaaa	agctgacca	3660
gaggccatac	agagcaggaa	tatcccattg	ccccctctc	cactgggttc	agagggtaag	3720
aaagcaccct	ccaataaacc	caggctccag	gccgtggggg	ctgctgaagg	ctctttcccc	3780
gcaagggcca	ggtgttgaca	ccttaaagct	ggcgccecca	gccccactct	tggtctgtct	3840
ggccagggtg	ctcctagttc	ttggccacat	catcagaaag	tcaaaggctc	cactccaggt	3900
ttggggctcc	ttccttccac	tcccctccct	gccagagtct	gtcttggeca	gtgccagcct	3960
cgatgctttg	gttttgacct	cacctgatcc	tcctttctc	atgcagcaca	agtgtccacc	4020
ggggccagag	ccagggcatg	gatatgacaa	gcagggcagc	ctggacactg	ccctcacagg	4080
acagcgccaa	taacaataca	gtgtctgagt	atctccaggg	gatgatttct	ggctctttgt	4140
ctccaatcag	tcccactccc	tcctgaggtc	cccaagggca	gtattcagag	aggtttctctg	4200
cgttttatct	ctatttggtg	tacctccac	tgttgcctcc	tgcctgtgtg	ggccttctgg	4260
ttgacctctg	cccgatcttc	tgtctctctg	agggaatcag	agtccagcat	ccagccccag	4320
ctggaacagc	tgaagtcaca	agcctcctct	aagccaaggc	cagtgtgttc	agaggtgact	4380
gccaccata	ctaggacaaa	cacagctcag	atcaccaggt	caagcaccta	ggcctggctt	4440
ctcctgagac	agaggactca	gaagtggcct	ttcctccaaa	gcctgctcag	acacaggtct	4500
gtagggccag	ggtgttctgc	ttggtgggccc	tgcagctgct	accctcgggt	tggggctgag	4560

-continued

tcagccagat	cctcccccta	cttctcccca	agggccaaga	actgctcagg	gacattaaag	4620
gtcaaaagtc	cagccacact	cattcatcct	ttccccaggc	ccatgaagag	aggcatctca	4680
ttgtagaatg	tatgaggaag	tgggaagtat	ctcagagaa	cagctaagtt	tcctaacttg	4740
tccatccaaa	tgtgatcacc	acgattcaac	aatttggggc	attgctgac	tagccgttcc	4800
tagtggggct	tgctcaaggt	tgcacagcga	gtcagtagaa	gcctggctg	gccccacttg	4860
gtaccaatcc	accaggcagc	tcagggtcc	tgcccagccc	agcagcttct	gttgtctaac	4920
gtatggcagg	cagactggga	gcaggaaaac	agagggcccc	aaagcccaag	gcaccagaag	4980
gtttgtttca	gtttgctgaa	gctgatttgt	aatgattggc	actcttcagc	caggggagtg	5040
ggtaggccat	agccaaggat	cgattcccca	accacagcaa	aggcaacact	cttctccag	5100
agatcaccaa	gcccctctta	cctccctccc	tccttcccaa	ggctggcact	aaccaggtag	5160
cacattcatt	gttaaggaat	ggctgatgac	tgctacacgt	gttgggaacc	tggtggggc	5220
tgtgcagttt	gggtggaag	gagagatgcc	agccctctg	ctgctctgg	tccttgaagt	5280
gtcacctctc	tcaggacctc	tcctctggcc	tgtggggtta	taagtgatgg	atagcagaaa	5340
gggagaactg	actcctgtcc	caaatagctc	ctctgccacc	tgtcctgcag	tgggcctgtg	5400
tgggttatga	ttctagatcc	tagacagagg	ctgggtcagc	tgtggatggg	gtgggtgctt	5460
ggtctctctt	gactacctcg	tccaaagaga	gcactgcctt	tagacaagag	ttgcttgtcc	5520
tgctgtgggc	tgggttcca	gctgcagacc	tccagttgct	tgggtttcac	tttgcctctc	5580
ttgccctctg	tcttctggtc	caggcagatc	aggggctctg	gggaaactgc	tggaaactcga	5640
ggtgaggatc	agccttttcc	agcatcctgt	gagagaccag	agagagagtt	tggatttcat	5700
gtggggaacc	ctcaaggcct	gtctggagaa	gtgacacagg	atttactggg	gtgggctggt	5760
ccaggtagct	ctctgaacc	tcctccttcc	ccaagctgag	aagctgagag	ctggaggaca	5820
atatccaggg	acatggctct	ggaaaataac	ttttttttt	ttaagagaca	gggtcttctg	5880
ctgttgccca	ggctggaggg	cagtgacata	atcatagctc	actgtaccct	tgaactcctg	5940
ggctcaagtg	atcctcctgc	ctcagcctcc	ttagtagctg	ggactaccag	tgcataccac	6000
catgcctggg	tgatttttta	aattttttat	acagacaagg	tcttctatg	tgcccaggc	6060
tgatcttgaa	ttccccggct	caagtggctc	tcctgcctca	gcctcccaca	ggatcgggat	6120
tacaggcaag	agcctccacg	cccggccatg	aaatataatt	cttaatatca	tacaggaaaa	6180
agtcagcggg	tcaagctagc	ctgtggccca	gccacaacta	gctgacaaag	cttctgggcc	6240
ttccctttaa	cacagttctg	ctgccatagt	tccatctata	aaatgggaat	ggagggaaat	6300
aggggaactg	ggatagagaa	cacagccttg	ccaagcagca	atgtagcct	gatccttctt	6360
ccacctagct	cgccatctcg	cccttgaaaa	atggctcctg	gaggattagg	cagccatctg	6420
caaggagagg	ggcaacctgg	gacaagacac	ccagagggta	aggattccag	gaatgaagct	6480
gccatttctg	gttgggagga	gaagaggaaa	cttttaagag	aaagggctcc	attatgagca	6540
tgggttcagg	gcctgcatt	acccaatcag	aacagccggg	atgagcagga	ggccagctcc	6600
caggaggaag	gggaaccctt	tcataaagtt	cagagtggct	gggtagagtg	agttgaagat	6660
gccggaggcc	gtcagcatgg	ccaggctatt	cacacaggcc	acagcagaaa	agagagcacc	6720
tgtgaagaaa	taaataccat	actctggagt	ccgaaagggc	catattccaa	ctctggcacc	6780
accacctcac	agctgtgtga	ccgggagtag	tcacttaacc	tatgtctccc	cttctcacc	6840
agtaaatcct	gtacatcat	gtactgtgac	aaggattcag	taaggtcata	tgtggacagt	6900

-continued

```

agctggcaca gaggggctac taaacaaatg gctgctatta aatccacatt aaaagtacat 6960
gtgatctgac agaaccgcagc acataaaaga aaaaaaaaaag t 7001

```

```

<210> SEQ ID NO 2
<211> LENGTH: 724
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens
<300> PUBLICATION INFORMATION:
<308> DATABASE ACCESSION NUMBER: GenBank Accession No. NP_055892

```

```

<400> SEQUENCE: 2

```

```

Met Val Leu Thr Leu Leu Leu Ser Ala Tyr Lys Leu Cys Arg Phe Phe
1           5           10          15
Ala Met Ser Gly Pro Arg Pro Gly Ala Glu Arg Leu Ala Val Pro Gly
20          25          30
Pro Asp Gly Gly Gly Thr Gly Pro Trp Trp Ala Ala Gly Gly Arg
35          40          45
Gly Pro Arg Glu Val Ser Pro Gly Ala Gly Thr Glu Val Gln Asp Ala
50          55          60
Leu Glu Arg Ala Leu Pro Glu Leu Gln Gln Ala Leu Ser Ala Leu Lys
65          70          75          80
Gln Ala Gly Gly Ala Arg Ala Val Gly Ala Gly Leu Ala Glu Val Phe
85          90          95
Gln Leu Val Glu Glu Ala Trp Leu Leu Pro Ala Val Gly Arg Glu Val
100         105         110
Ala Gln Gly Leu Cys Asp Ala Ile Arg Leu Asp Gly Gly Leu Asp Leu
115        120        125
Leu Leu Arg Leu Leu Gln Ala Pro Glu Leu Glu Thr Arg Val Gln Ala
130        135        140
Ala Arg Leu Leu Glu Gln Ile Leu Val Ala Glu Asn Arg Asp Arg Val
145        150        155        160
Ala Arg Ile Gly Leu Gly Val Ile Leu Asn Leu Ala Lys Glu Arg Glu
165        170        175
Pro Val Glu Leu Ala Arg Ser Val Ala Gly Ile Leu Glu His Met Phe
180        185        190
Lys His Ser Glu Glu Thr Cys Gln Arg Leu Val Ala Ala Gly Gly Leu
195        200        205
Asp Ala Val Leu Tyr Trp Cys Arg Arg Thr Asp Pro Ala Leu Leu Arg
210        215        220
His Cys Ala Leu Ala Leu Gly Asn Cys Ala Leu His Gly Gly Gln Ala
225        230        235        240
Val Gln Arg Arg Met Val Glu Lys Arg Ala Ala Glu Trp Leu Phe Pro
245        250        255
Leu Ala Phe Ser Lys Glu Asp Glu Leu Leu Arg Leu His Ala Cys Leu
260        265        270
Ala Val Ala Val Leu Ala Thr Asn Lys Glu Val Glu Arg Glu Val Glu
275        280        285
Arg Ser Gly Thr Leu Ala Leu Val Glu Pro Leu Val Ala Ser Leu Asp
290        295        300
Pro Gly Arg Phe Ala Arg Cys Leu Val Asp Ala Ser Asp Thr Ser Gln
305        310        315        320
Gly Arg Gly Pro Asp Asp Leu Gln Arg Leu Val Pro Leu Leu Asp Ser
325        330        335

```

-continued

Asn Arg Leu Glu Ala Gln Cys Ile Gly Ala Phe Tyr Leu Cys Ala Glu
 340 345 350
 Ala Ala Ile Lys Ser Leu Gln Gly Lys Thr Lys Val Phe Ser Asp Ile
 355 360 365
 Gly Ala Ile Gln Ser Leu Lys Arg Leu Val Ser Tyr Ser Thr Asn Gly
 370 375 380
 Thr Lys Ser Ala Leu Ala Lys Arg Ala Leu Arg Leu Leu Gly Glu Glu
 385 390 395 400
 Val Pro Arg Pro Ile Leu Pro Ser Val Pro Ser Trp Lys Glu Ala Glu
 405 410 415
 Val Gln Thr Trp Leu Gln Gln Ile Gly Phe Ser Lys Tyr Cys Glu Ser
 420 425 430
 Phe Arg Glu Gln Gln Val Asp Gly Asp Leu Leu Leu Arg Leu Thr Glu
 435 440 445
 Glu Glu Leu Gln Thr Asp Leu Gly Met Lys Ser Gly Ile Thr Arg Lys
 450 455 460
 Arg Phe Phe Arg Glu Leu Thr Glu Leu Lys Thr Phe Ala Asn Tyr Ser
 465 470 475 480
 Thr Cys Asp Arg Ser Asn Leu Ala Asp Trp Leu Gly Ser Leu Asp Pro
 485 490 495
 Arg Phe Arg Gln Tyr Thr Tyr Gly Leu Val Ser Cys Gly Leu Asp Arg
 500 505 510
 Ser Leu Leu His Arg Val Ser Glu Gln Gln Leu Leu Glu Asp Cys Gly
 515 520 525
 Ile His Leu Gly Val His Arg Ala Arg Ile Leu Thr Ala Ala Arg Glu
 530 535 540
 Met Leu His Ser Pro Leu Pro Cys Thr Gly Gly Lys Pro Ser Gly Asp
 545 550 555 560
 Thr Pro Asp Val Phe Ile Ser Tyr Arg Arg Asn Ser Gly Ser Gln Leu
 565 570 575
 Ala Ser Leu Leu Lys Val His Leu Gln Leu His Gly Phe Ser Val Phe
 580 585 590
 Ile Asp Val Glu Lys Leu Glu Ala Gly Lys Phe Glu Asp Lys Leu Ile
 595 600 605
 Gln Ser Val Met Gly Ala Arg Asn Phe Val Leu Val Leu Ser Pro Gly
 610 615 620
 Ala Leu Asp Lys Cys Met Gln Asp His Asp Cys Lys Asp Trp Val His
 625 630 635 640
 Lys Glu Ile Val Thr Ala Leu Ser Cys Gly Lys Asn Ile Val Pro Ile
 645 650 655
 Ile Asp Gly Phe Glu Trp Pro Glu Pro Gln Val Leu Pro Glu Asp Met
 660 665 670
 Gln Ala Val Leu Thr Phe Asn Gly Ile Lys Trp Ser His Glu Tyr Gln
 675 680 685
 Glu Ala Thr Ile Glu Lys Ile Ile Arg Phe Leu Gln Gly Arg Ser Ser
 690 695 700
 Arg Asp Ser Ser Ala Gly Ser Asp Thr Ser Leu Glu Gly Ala Ala Pro
 705 710 715 720
 Met Gly Pro Thr

-continued

```

<211> LENGTH: 5164
<212> TYPE: DNA
<213> ORGANISM: Mus musculus
<300> PUBLICATION INFORMATION:
<308> DATABASE ACCESSION NUMBER: GenBank Accession No. NM_001168521

<400> SEQUENCE: 3

ctgttgagca tcttagctcc gctgtgctta gattggagca gcgctttgtt ccgggcaccg      60
gcgtctctac cctcccgcgt ctggtccatg cttctctctc cttcatgcc ctctctaagt      120
cgctgagtcc cggagctgcc ctccctcttc tgcttctaca cttgtagccc agcaccttta      180
ccggatcctg tttgcttttt tttttttttt tttttttett tctctccca aggccggggt      240
ctctctgcca ggccccgcc ctctaggcct ggcattgtccc ctgctgcccc gcgccatgg      300
tcctgacgct gctcttctcc gcctacaaac tgtgccgctt cttcaccatg tcaggcccac      360
ggccgggggc cgatcggtcg acagtgcccg gaccggatcg gagtgggtggc gccagcccat      420
ggtgggtgct gggcggtcgc gggctctcgc aagtgtcgc ccgagtgggc actgaggtgc      480
aaggcgccct ggagcgttcg ctgcctgagc tgcagcaggc gctgtccgag ctgaaacagg      540
caagcgcggc gcgggctgtg ggcgcgggtc tcgcccaggc cttccagctg gtagaggaag      600
cctggctgct gccggccgtg gcccgcgagg tggcccaagg tctatgcgat gctatacgtc      660
tgagcgggtg cctcgacttg ctggtgcggc tgcttcaggg accggagcta gagaccctg      720
tgcaggccgc gcgcttctg gagcagatcc tgggtggtga gaaccgggac cgcgtggcgc      780
gcatcggtct aggcgtgac ttgaacctgg cgaaggagcg cgagcctgtg gaactggcac      840
gaagcgtggc gggcatcttg gagcacatgt tcaagcactc ggaggagacg tgccagcggc      900
tggtggcggc cggagccctc gacgcgggtc tgtactggtg ccgccgcaca gaccggcggc      960
tgctgcgcca ctgcctctt gcgctggcga actgcgcgct gcacgggggc cagacggtgc     1020
agcggtgcat ggtggagaag cgcgcgcgcg agtggtctct cccgctcgtt ttctccaagg     1080
aggacgagct gctgcggtg cacgcctgcc tggcgggtgg ggtgttggtt accaacaagg     1140
aggtggaacg cgaggtcgag cttcttgga cattggcgtc tgtcgagccg ctctgggcat     1200
cgctggaccg cggccgcttc gcccgctgcc tgggtgatgc cagtgcacac agccagggtc     1260
gtggaccaga cgacctgcag agcctggtgc tgttgctcga ttcgtcgcgt ttggaggctc     1320
agtgcatagg agcattctac ctgtgcgcag aggctgccat caagagccta cagggaaaga     1380
ccaaggtggt cagcgacatc ggcgctatcc agagcctgaa acgctggtt tcttactcta     1440
cgaatggcac cacgtcggcg ctggccaagc gcgcgctgcy cctattgggc gaggaggtgc     1500
caagcgcat cctgccctgc gtggccagct ggaaggaagc tgaggtccag acctggctac     1560
agcagatcgg cttctcccag tactgcgaga acttccggga gcagcaggta gatggtgacc     1620
tgcttctaag actcacagat gaagaactcc agacagacct aggcattgaaa tcaagcatca     1680
cccgaagag gttcttttag gagctcacag agctcaagac cttcggcagc tacgctactt     1740
gcgaccgcag caacctagcg gactggctgg gcagcctgga tcctcgttc cgccagtaca     1800
cctatggcct ggtcagctgc ggtctggacc gctccctgct gcaccgcgtg tcagagcagc     1860
agctcctgga ggactgtggc atccgcctgg gagtgaccg cacgcgcac ctctctgcag     1920
ccagaggtea ctttgcccag actggcctga gaagcttgag gagaccaagt ctccacgatg     1980
atggaccccg tgataagcag tggggaagag ccaccctcac ctccatgtct ctttccttgg     2040
ctccagaaat getacattcc ccgctgcct gtactggagg caagctcagt ggggacacc     2100

```


-continued

cagatgtctt	tatcagttac	cgagggaact	caggggtccca	gctggccagc	ctcctgaagg	2160
tgcacctgca	gcttcacggc	ttcagcgtct	tcacgcagct	ggagaagctg	gaagccggca	2220
aattcgagga	caagcttata	caaagcgtca	tagcggctcg	caattttgtc	ctggtgctgt	2280
ctgtggggc	gctggataag	tgcatgcagg	accatgactg	caaggactgg	gtgcacaagg	2340
agattgtgac	tgetttaagc	tgtggcaaga	acattgtgcc	catcattgat	ggctttgagt	2400
ggcctgagcc	tcaggcgtg	cctgaggata	tgaggctgt	actcaccttc	aacggcatca	2460
aatgggtccca	tgagtaccag	gagggccacca	tcgagaagat	catccgcttc	ctacagggcc	2520
gcccctctca	ggactcctct	gccggatcgg	ataccagttt	ggagggagct	acgccaatgg	2580
gtctgctta	acctgtcccc	agttcccgctg	ccctactgtg	actcctgatt	tagttccctg	2640
cccttaaagg	aatagctcct	ctagatgccca	ccctgactga	ggcaaaccag	actgtttctca	2700
ggcaatggct	ttcccggtg	ccactctgtg	gcccacttct	aatccagaga	tgccaggcac	2760
aggttagatg	agaggacact	cctgtgtcag	gccctgccat	caggaccacg	ctcccatgca	2820
gaaccatgtc	cctgcttagt	tctggacatc	caagacaggg	gaagaacatt	tcccatctc	2880
ctgacctgag	agcagccagc	ttgagtaagg	tgaggttgcc	agcctcccat	aagggtcaat	2940
acaacgcctg	gatccccaaa	cctgtgctca	ggaggaagct	ggggctgaga	atccccaaag	3000
gctatctact	cacattgtgc	ctggacccgg	gctcacctgg	cttcctcctg	cctcatggcc	3060
ttgctctgta	actacctggt	accccttcta	gacttccttt	aggcagcctc	ctttggcata	3120
ttgggagtea	gggtgtggct	gaactggacc	tctgcctggc	cttggtgtgc	ctcctgggtg	3180
aagaaggggt	gctttgctta	tgcaaggaga	ccataagagc	tcactctagc	ccaaccttt	3240
gtcgtgcct	aaggctctta	cctagcctgc	tccatctgac	ttcccagct	cctcacccac	3300
acagagcttg	tcaccacact	gctcagggaa	gccccaacac	caccagtagc	ccgagcagaa	3360
cctgcaccat	gggaaaaaag	caagccatcc	acaggcaagg	gctaattcct	ggggcagttt	3420
ctcccaccga	agtgtgtcaa	atccattggg	aatctcatca	aaattcagag	caggccacct	3480
gggaagcacc	tgggcctctg	catttttcag	attcccagga	gagctgatga	aagagagccc	3540
tactaatcc	agccattcca	aacacccccca	ccctgggtccc	tgatcatcac	aacagccttt	3600
tcctctctcc	agttttacag	agctgagtgg	ctgagtgatg	ggatcaggtc	cccagttat	3660
tgggtgcagc	ctcaggatct	tgcttagtgc	ctggtaccca	gatctgttct	cctgagactc	3720
atccaagagg	ctgtggccca	tgcttggtag	ctgcctctcc	ctggccacaa	agaactgagc	3780
agtgcaggg	gggtcttgac	taaaagggtg	agctaagggc	atatagaatg	tcccatgtcc	3840
ctccctccac	tggacaagaa	aggcaagaaa	gctggctctt	gccattaccc	aggctcaage	3900
tcagagagct	ggcaccaccc	tgctgtcgtc	ttctggaggc	catgggttca	cacctctcct	3960
gaggctagcc	aggttacttg	cccacggccc	acattatcag	agagccaaag	ggctttctct	4020
ccaggcctgg	ggacactttc	ctcctaccgt	ccatcttcca	tgggtcatgg	ctggcctctg	4080
gctgtgacta	tttgagttt	tgtcaccagg	aacaaccccc	gcatcctatt	ctgaggtgag	4140
gcagatggaa	tggatcctt	gatgacaaat	tcaatgacaa	tacagtgtat	gagttcaccc	4200
taaggaaatg	tctgtcttca	gtcccatact	ctccagtggt	ccctgtgggc	agtacttaag	4260
aaatttctg	ttttccttgt	ttggggcaca	agtcactact	acctccactg	tctggccttc	4320
tgttgatctg	tcccctactg	tcttcttggg	gaaccagagc	acagccttat	gtcccagcca	4380

-continued

```

ggatagcaaa agtgtcaage ctctctagc tagacagtac actgtgtggt gacagagggc 4440
ctcaacttct gctaagcatg gctgaccaca ctgatcttga gacaggctct tcagtagccc 4500
ttcaagcage ccacactcgc atggtctgtg ggttcagggt ttcttctag ctgagctata 4560
gctgtgcccc ccagattggg gcctagtcag ggagatccct actcttcaac acccaccgtc 4620
tctagggagc tacgaactgc ttaggaacat taagaggeta aagatccagc cagtttgttc 4680
atccttcact gagcatctca tcctgggatg tatggagctg gagggatctc agagcatcca 4740
acagctgtgc ttctaacgc atccagttag gtccttgtag acagatgtgg gggagtgtg 4800
atccagtttt ctctagatgt gctcaaggtc acatgctgcc agagtgaagc ctttccctcc 4860
tcacagcctc agggcagtg ggttagtgga aagcctcttc ttgcttagac ttttctattt 4920
ccagagggac agtgaagcag aagtgtgga gccagatggg ccctggtgca gttcagtg 4980
ccttagtttt ccctgggatg tatctcttcc acctgcatgg tttccagctg ggaaactagc 5040
ttgcagtttg ggcaggaaga gatagcttca tcaaagacag tggcttccca ttagataaga 5100
ttctaccttt cagttttgag cccaggtctt tocaacacgc cacacatata cacacacaca 5160
caca 5164

```

<210> SEQ ID NO 4

<211> LENGTH: 764

<212> TYPE: PRT

<213> ORGANISM: Mus musculus

<300> PUBLICATION INFORMATION:

<308> DATABASE ACCESSION NUMBER: GenBank Accession No. NP_001161993

<400> SEQUENCE: 4

```

Met Val Leu Thr Leu Leu Phe Ser Ala Tyr Lys Leu Cys Arg Phe Phe
1 5 10 15
Thr Met Ser Gly Pro Arg Pro Gly Ala Asp Arg Leu Thr Val Pro Gly
20 25 30
Pro Asp Arg Ser Gly Gly Ala Ser Pro Trp Trp Ala Ala Gly Gly Arg
35 40 45
Gly Ser Arg Glu Val Ser Pro Gly Val Gly Thr Glu Val Gln Gly Ala
50 55 60
Leu Glu Arg Ser Leu Pro Glu Leu Gln Gln Ala Leu Ser Glu Leu Lys
65 70 75 80
Gln Ala Ser Ala Ala Arg Ala Val Gly Ala Gly Leu Ala Glu Val Phe
85 90 95
Gln Leu Val Glu Glu Ala Trp Leu Leu Pro Ala Val Gly Arg Glu Val
100 105 110
Ala Gln Gly Leu Cys Asp Ala Ile Arg Leu Asp Gly Gly Leu Asp Leu
115 120 125
Leu Leu Arg Leu Leu Gln Ala Pro Glu Leu Glu Thr Arg Val Gln Ala
130 135 140
Ala Arg Leu Leu Glu Gln Ile Leu Val Ala Glu Asn Arg Asp Arg Val
145 150 155 160
Ala Arg Ile Gly Leu Gly Val Ile Leu Asn Leu Ala Lys Glu Arg Glu
165 170 175
Pro Val Glu Leu Ala Arg Ser Val Ala Gly Ile Leu Glu His Met Phe
180 185 190
Lys His Ser Glu Glu Thr Cys Gln Arg Leu Val Ala Ala Gly Gly Leu
195 200 205

```

-continued

Asp	Ala	Val	Leu	Tyr	Trp	Cys	Arg	Arg	Thr	Asp	Pro	Ala	Leu	Leu	Arg
210						215					220				
His	Cys	Ala	Leu	Ala	Leu	Ala	Asn	Cys	Ala	Leu	His	Gly	Gly	Gln	Thr
225					230					235					240
Val	Gln	Arg	Cys	Met	Val	Glu	Lys	Arg	Ala	Ala	Glu	Trp	Leu	Phe	Pro
				245					250					255	
Leu	Ala	Phe	Ser	Lys	Glu	Asp	Glu	Leu	Leu	Arg	Leu	His	Ala	Cys	Leu
			260					265					270		
Ala	Val	Ala	Val	Leu	Ala	Thr	Asn	Lys	Glu	Val	Glu	Arg	Glu	Val	Glu
		275					280					285			
His	Ser	Gly	Thr	Leu	Ala	Leu	Val	Glu	Pro	Leu	Val	Ala	Ser	Leu	Asp
	290					295					300				
Pro	Gly	Arg	Phe	Ala	Arg	Cys	Leu	Val	Asp	Ala	Ser	Asp	Thr	Ser	Gln
305					310					315					320
Gly	Arg	Gly	Pro	Asp	Asp	Leu	Gln	Ser	Leu	Val	Leu	Leu	Leu	Asp	Ser
				325					330					335	
Ser	Arg	Leu	Glu	Ala	Gln	Cys	Ile	Gly	Ala	Phe	Tyr	Leu	Cys	Ala	Glu
			340					345					350		
Ala	Ala	Ile	Lys	Ser	Leu	Gln	Gly	Lys	Thr	Lys	Val	Phe	Ser	Asp	Ile
		355					360					365			
Gly	Ala	Ile	Gln	Ser	Leu	Lys	Arg	Leu	Val	Ser	Tyr	Ser	Thr	Asn	Gly
	370					375					380				
Thr	Thr	Ser	Ala	Leu	Ala	Lys	Arg	Ala	Leu	Arg	Leu	Leu	Gly	Glu	Glu
385					390					395					400
Val	Pro	Arg	Arg	Ile	Leu	Pro	Cys	Val	Ala	Ser	Trp	Lys	Glu	Ala	Glu
				405					410					415	
Val	Gln	Thr	Trp	Leu	Gln	Gln	Ile	Gly	Phe	Ser	Gln	Tyr	Cys	Glu	Asn
			420					425					430		
Phe	Arg	Glu	Gln	Gln	Val	Asp	Gly	Asp	Leu	Leu	Leu	Arg	Leu	Thr	Asp
		435					440					445			
Glu	Glu	Leu	Gln	Thr	Asp	Leu	Gly	Met	Lys	Ser	Ser	Ile	Thr	Arg	Lys
	450					455					460				
Arg	Phe	Phe	Arg	Glu	Leu	Thr	Glu	Leu	Lys	Thr	Phe	Ala	Ser	Tyr	Ala
465					470					475					480
Thr	Cys	Asp	Arg	Ser	Asn	Leu	Ala	Asp	Trp	Leu	Gly	Ser	Leu	Asp	Pro
				485					490					495	
Arg	Phe	Arg	Gln	Tyr	Thr	Tyr	Gly	Leu	Val	Ser	Cys	Gly	Leu	Asp	Arg
			500					505					510		
Ser	Leu	Leu	His	Arg	Val	Ser	Glu	Gln	Gln	Leu	Leu	Glu	Asp	Cys	Gly
		515					520					525			
Ile	Arg	Leu	Gly	Val	His	Arg	Thr	Arg	Ile	Leu	Ser	Ala	Ala	Arg	Gly
	530					535					540				
His	Phe	Ala	Gln	Thr	Gly	Leu	Arg	Ser	Leu	Arg	Arg	Pro	Ser	Leu	His
545					550					555					560
Asp	Asp	Gly	Pro	Arg	Asp	Lys	Gln	Trp	Gly	Arg	Ala	Thr	Leu	Thr	Ser
				565					570					575	
Met	Ser	Leu	Ser	Leu	Ala	Pro	Glu	Met	Leu	His	Ser	Pro	Leu	Pro	Cys
			580					585					590		
Thr	Gly	Gly	Lys	Leu	Ser	Gly	Asp	Thr	Pro	Asp	Val	Phe	Ile	Ser	Tyr
		595					600					605			
Arg	Arg	Asn	Ser	Gly	Ser	Gln	Leu	Ala	Ser	Leu	Leu	Lys	Val	His	Leu
	610					615					620				

-continued

Gln Leu His Gly Phe Ser Val Phe Ile Asp Val Glu Lys Leu Glu Ala
 625 630 635 640
 Gly Lys Phe Glu Asp Lys Leu Ile Gln Ser Val Ile Ala Ala Arg Asn
 645 650 655
 Phe Val Leu Val Leu Ser Ala Gly Ala Leu Asp Lys Cys Met Gln Asp
 660 665 670
 His Asp Cys Lys Asp Trp Val His Lys Glu Ile Val Thr Ala Leu Ser
 675 680 685
 Cys Gly Lys Asn Ile Val Pro Ile Ile Asp Gly Phe Glu Trp Pro Glu
 690 695 700
 Pro Gln Ala Leu Pro Glu Asp Met Gln Ala Val Leu Thr Phe Asn Gly
 705 710 715 720
 Ile Lys Trp Ser His Glu Tyr Gln Glu Ala Thr Ile Glu Lys Ile Ile
 725 730 735
 Arg Phe Leu Gln Gly Arg Pro Ser Gln Asp Ser Ser Ala Gly Ser Asp
 740 745 750
 Thr Ser Leu Glu Gly Ala Thr Pro Met Gly Leu Pro
 755 760

<210> SEQ ID NO 5
 <211> LENGTH: 5044
 <212> TYPE: DNA
 <213> ORGANISM: Mus musculus
 <300> PUBLICATION INFORMATION:
 <308> DATABASE ACCESSION NUMBER: GenBank Accession No. NM_172795
 <400> SEQUENCE: 5

ctgttgagca tcttagctcc gctgtgctta gattggagca gcgctttggt ccgggcaccg 60
 gcgtctctac cctcccgcgt ctggtccatg cttctctctc cttcatgcc cttcctaagt 120
 cgctgagtcc cggagctgcc ctctccttc tgcttctaca cttgtagccc agcaccttta 180
 ccggatcctg tttgcttttt tttttttttt tttttttett tctcctccca aggcgggggt 240
 ctctctgccca ggccccgccc ctctaggcct ggcattgtccc ctgctgcccc gcgcccattg 300
 tctgacgct gctcttctcc gcctacaaac tgtgcccgtt cttaccatg tcaggcccac 360
 ggccgggggc cgatecggctg acagtgcccg gaccggatcg gagggtgggc gccagcccat 420
 ggtgggctgc gggcggtcgc gggctctcgc aagtgtcgc cggagtgggc actgaggtgc 480
 aaggcgcctt ggagcgttcg ctgcctgagc tgcagcaggc gctgtccgag ctgaaacagg 540
 caagcgcggc gcgggctgtg ggcgcgggtc tcgccgaggt cttccagctg gtagaggaag 600
 cctggctgct gccggccgtg gcccgcgagg tggcccaagg tctatcgat gctatactc 660
 tggacggtgg cctcgacttg ctggtgcggc tgcttcaggc accggagcta gagaccgtg 720
 tgcaggccgc gcgcttctg gagcagatcc tgggtggtga gaaccgggac cgcgtggcgc 780
 gcatcggctt aggcgtgatc ttgaacctgg cgaaggagcg cgagcctgtg gaactggcac 840
 gaagcgtggc gggcatcttg gagcacatgt tcaagcactc ggaggagacg tgccagcggc 900
 tgggtggcgc cggaggcctc gacgcgggtc tgtactggtg ccgcccacac gaccggcgc 960
 tgctgcgccca ctgcctctt gcgctggcga actgcgcgct gcacgggggc cagacggtgc 1020
 agcgggtgcat ggtggagaag cgcgcgcggc agtggctctt cccgctcgtt ttctccaagg 1080
 aggacgagct gctgcggctg cagcctgcc tggcggtggc ggtgttggtt accaacaagg 1140
 aggtggaacg cgaggtcgag cattctggca cattggcgtt tgcgagccg ctggtggcat 1200

-continued

cgctggacce	cgcccgttc	gcccgtgcc	tggtggatgc	cagtgacaca	agccagggtc	1260
gtggaccaga	cgacctgcag	agcctgggtc	tggtgctcga	ttcgtcgcgt	ttggaggctc	1320
agtgcatagg	agcattctac	ctgtgcgcag	aggctgceat	caagagccta	cagggaaaga	1380
ccaagtggtt	cagcgacatc	ggcgctatcc	agagcctgaa	acgcctggtt	tcttactcta	1440
cgaatggcac	cacgtcggcg	ctggccaagc	gocgcctgcy	cctattgggc	gaggagggtc	1500
caaggcgcac	cctgcacctc	gtggccagct	ggaaggaagc	tgaggccag	acctggctac	1560
agcagatcgg	cttctcccag	tactgcgaga	actttcggga	gcagcaggta	gatggtgacc	1620
tgcttctaag	actcacagat	gaagaactcc	agacagacct	aggcatgaaa	tcaagcatca	1680
cccgaagag	gttcttagg	gagctcacag	agctcaagac	cttcgccagc	tacgtactt	1740
gcgaccgcag	caacctagcg	gactggctgg	gcagcctgga	tcctcgcttc	cgccagtaca	1800
cctatggcct	ggtcagctgc	ggtctggacc	gctccctgct	gcaccgcgtg	tcagagcagc	1860
agctcctgga	ggactgtggc	atccgcctgg	gagtgcaacc	cacgcgcate	ctctctgcag	1920
ccagagaaat	gtacattcc	ccgctgcctc	gtactggagg	caagctcagt	ggggacaccc	1980
caagatgtct	tatcagttac	cggaggaact	cagggtccca	gctggccagc	ctctgaagg	2040
tgcacctgca	gcttcacggc	ttcagcgtct	tcacgcagct	ggagaagctg	gaagccggca	2100
aattcgagga	caagcttacc	caaagcgtca	tagcggctcg	caattttgtc	ctggtgctgt	2160
ctgctggggc	gctggataag	tgcatgcagg	accatgactg	caaggactgg	gtgcacaagg	2220
agattgtgac	tgctttaagc	tgtggcaaga	acattgtgcc	catcattgat	ggctttgagt	2280
ggcctgagcc	tcaggcgcgt	cctgaggata	tgaggctgt	actcaccttc	aacggcatca	2340
aatggtccca	tgagtaccag	gagggccacca	tcgagaagat	catccgcttc	ctacagggcc	2400
gcccctctca	ggactcctct	gcccgatcgg	ataccagttt	ggagggagct	acgccaatgg	2460
gtctgcctta	acctgtcccc	agttcccgtg	ccctactgtg	actcctgatt	tagttccctg	2520
cccttaaagg	aatagctcct	ctagatgcca	ccctgactga	ggcaaacccag	actgttctca	2580
ggcaatggct	ttcccggctg	ccactctgtg	gcccacttct	aatccagaga	tgccaggcac	2640
aggttagatg	agaggacact	cctgtgtcag	gcccctgcat	caggaccacg	ctcccatgca	2700
gaacatgtc	cctgcttagt	tctggacatc	caagacaggg	gaagaacatt	tcccctctc	2760
ctgacctgag	agcagccagc	ttgagtaagg	tgaggttgcc	agcctcccat	aagggtcaat	2820
acaacgcctg	gatcccaaaa	cctgtgctca	ggaggaagct	ggggctgaga	atccccaag	2880
gctatctact	cacattgtgc	ctggaccccg	gctcacctgg	cttcctctcg	cctcatggcc	2940
ttgctctgta	actacctggt	accccttcta	gacttccttt	aggcagcctc	ctttggcata	3000
ttgggagtca	gggtgtggct	gaactggacc	tctgcctggc	cttgttctc	ctcctgggtc	3060
aagaaggggt	gctttgctta	tgcaaggaga	ccataagagc	tcactctagc	ccaaaccttt	3120
gtgcgtgcct	aaggctctta	cctagcctgc	tccatctgac	ttcccagct	cctcaccac	3180
acagagcttg	tcaccacctc	gctcagggaa	gccccaacac	caccagtagc	ccgagcagaa	3240
cctgcaccat	gggaaaaagg	caagccatcc	acaggcaagg	gctaattcct	ggggcagttt	3300
ctcccaccga	agtgtgtcaa	atccattggg	aatctcatca	aaattcagag	caggccacct	3360
gggaagcacc	tgggcctctg	catttttcag	attcccagga	gagctgatga	aagagagccc	3420
tcactaatcc	agccattcca	aacaccccca	ccctggctcc	tgatcatcac	aacagccttt	3480

-continued

```

tcctctctcc agttttacag agctgagtggt ctgagtgatg ggatcaggtc cccaagttat 3540
tggtggcagc ctcaggatct tgccttagtc ctggtacca gatctgttct cctgagactc 3600
atccaagagg ctgtggccca tgcttgtag ctgcctctcc ctggccacaa agaactgagc 3660
agtgcagggg gggctctgac taaaaggtgg agctaagggc atatagaatg tcccatgtcc 3720
ctccctccac tggacaagaa aggcaagaaa gctggctett gccattacc aggctcaagc 3780
tcagagagct ggcaccacc tgctgtctgc ttctggaggc catggggtca cacctctcct 3840
gaggctagcc aggttacttg cccacggccc acattatcag agagccaaag ggctttctct 3900
ccaggcctgg ggacactttc ctccctaccgt ccatcttcca tgggtcatgg ctggcctctg 3960
gctgtgacta tttgcagttt tgtcaccagg aacaaccccc gcatcctatt ctgaggtgag 4020
gcagatggaa tggatcctt gatgacaaat tcaatgacaa tacagtgtat gaggttcacc 4080
taaggaaatg tctgtcttca gtcccatact ctccagtggt ccctgtgggc agtacttaag 4140
aaatttctgg ttttctctgt ttggggcaca agtcactact acctccactg tctggccttc 4200
tgttgatctg tcccctactg tcttcttggg gaaccagagc acagccttat gtcccagcca 4260
ggatagcaaa agtgtaagc ctccctctagc tagacagtac actgtgtggt gacagagggc 4320
ctcaacttct gtaagcatg gctgaccaca ctgatcttga gacaggctct tcagtagccc 4380
ttcaagcagc ccacactcgc atggtctgtg gggtcagggt ttcttctag ctgagctata 4440
gctgtgccc ccagattggg gcttagtcag ggagatcct actettcaac acccaccgtc 4500
tctagggagc tacgaactgc ttaggaacat taagaggcta aagatccagc cagtttgttc 4560
atccttcact gagcatctca tcttgggatg tatggagctg gagggatctc agagcatcca 4620
acagctgtgc ttcttaacgc atccagttag gtccttgca acagatgtgg gggagtgctg 4680
atccagtttt ctctagatgt gctcaaggtc acatgctgcc agagtgaagc ctttccctcc 4740
tcacagcctc agggcagtggt ggttagtgga aagcctcttc ttgcttagac ttttctattt 4800
ccagagggac agtgaagcag aagtgtggaa gccagatggg ccctgggtgca gttcagtggt 4860
ccttagtttt ccctgggatg tatctcttcc acctgcatgg tttccagctg ggaactagc 4920
ttgcagtttg ggcaggaaga gatagcttca tcaaagacag tggttccca ttagataaga 4980
ttctaccttt cagttttgag cccaggtctt tccaacacgc cacacatata cacacacaca 5040
caca 5044

```

```

<210> SEQ ID NO 6
<211> LENGTH: 724
<212> TYPE: PRT
<213> ORGANISM: Mus musculus
<300> PUBLICATION INFORMATION:
<308> DATABASE ACCESSION NUMBER: GenBank Accession No. NP_766383

```

```

<400> SEQUENCE: 6

```

```

Met Val Leu Thr Leu Leu Phe Ser Ala Tyr Lys Leu Cys Arg Phe Phe
1           5           10          15

Thr Met Ser Gly Pro Arg Pro Gly Ala Asp Arg Leu Thr Val Pro Gly
20          25          30

Pro Asp Arg Ser Gly Gly Ala Ser Pro Trp Trp Ala Ala Gly Gly Arg
35          40          45

Gly Ser Arg Glu Val Ser Pro Gly Val Gly Thr Glu Val Gln Gly Ala
50          55          60

Leu Glu Arg Ser Leu Pro Glu Leu Gln Gln Ala Leu Ser Glu Leu Lys

```

-continued

65	70	75	80
Gln Ala Ser Ala Ala Arg Ala Val Gly Ala Gly Leu Ala Glu Val Phe	85	90	95
Gln Leu Val Glu Glu Ala Trp Leu Leu Pro Ala Val Gly Arg Glu Val	100	105	110
Ala Gln Gly Leu Cys Asp Ala Ile Arg Leu Asp Gly Gly Leu Asp Leu	115	120	125
Leu Leu Arg Leu Leu Gln Ala Pro Glu Leu Glu Thr Arg Val Gln Ala	130	135	140
Ala Arg Leu Leu Glu Gln Ile Leu Val Ala Glu Asn Arg Asp Arg Val	145	150	155
Ala Arg Ile Gly Leu Gly Val Ile Leu Asn Leu Ala Lys Glu Arg Glu	165	170	175
Pro Val Glu Leu Ala Arg Ser Val Ala Gly Ile Leu Glu His Met Phe	180	185	190
Lys His Ser Glu Glu Thr Cys Gln Arg Leu Val Ala Ala Gly Gly Leu	195	200	205
Asp Ala Val Leu Tyr Trp Cys Arg Arg Thr Asp Pro Ala Leu Leu Arg	210	215	220
His Cys Ala Leu Ala Leu Ala Asn Cys Ala Leu His Gly Gly Gln Thr	225	230	235
Val Gln Arg Cys Met Val Glu Lys Arg Ala Ala Glu Trp Leu Phe Pro	245	250	255
Leu Ala Phe Ser Lys Glu Asp Glu Leu Leu Arg Leu His Ala Cys Leu	260	265	270
Ala Val Ala Val Leu Ala Thr Asn Lys Glu Val Glu Arg Glu Val Glu	275	280	285
His Ser Gly Thr Leu Ala Leu Val Glu Pro Leu Val Ala Ser Leu Asp	290	295	300
Pro Gly Arg Phe Ala Arg Cys Leu Val Asp Ala Ser Asp Thr Ser Gln	305	310	315
Gly Arg Gly Pro Asp Asp Leu Gln Ser Leu Val Leu Leu Leu Asp Ser	325	330	335
Ser Arg Leu Glu Ala Gln Cys Ile Gly Ala Phe Tyr Leu Cys Ala Glu	340	345	350
Ala Ala Ile Lys Ser Leu Gln Gly Lys Thr Lys Val Phe Ser Asp Ile	355	360	365
Gly Ala Ile Gln Ser Leu Lys Arg Leu Val Ser Tyr Ser Thr Asn Gly	370	375	380
Thr Thr Ser Ala Leu Ala Lys Arg Ala Leu Arg Leu Leu Gly Glu Glu	385	390	395
Val Pro Arg Arg Ile Leu Pro Cys Val Ala Ser Trp Lys Glu Ala Glu	405	410	415
Val Gln Thr Trp Leu Gln Gln Ile Gly Phe Ser Gln Tyr Cys Glu Asn	420	425	430
Phe Arg Glu Gln Gln Val Asp Gly Asp Leu Leu Leu Arg Leu Thr Asp	435	440	445
Glu Glu Leu Gln Thr Asp Leu Gly Met Lys Ser Ser Ile Thr Arg Lys	450	455	460
Arg Phe Phe Arg Glu Leu Thr Glu Leu Lys Thr Phe Ala Ser Tyr Ala	465	470	475
			480

-continued

Thr Cys Asp Arg Ser Asn Leu Ala Asp Trp Leu Gly Ser Leu Asp Pro
 485 490 495

Arg Phe Arg Gln Tyr Thr Tyr Gly Leu Val Ser Cys Gly Leu Asp Arg
 500 505 510

Ser Leu Leu His Arg Val Ser Glu Gln Gln Leu Leu Glu Asp Cys Gly
 515 520 525

Ile Arg Leu Gly Val His Arg Thr Arg Ile Leu Ser Ala Ala Arg Glu
 530 535 540

Met Leu His Ser Pro Leu Pro Cys Thr Gly Gly Lys Leu Ser Gly Asp
 545 550 555 560

Thr Pro Asp Val Phe Ile Ser Tyr Arg Arg Asn Ser Gly Ser Gln Leu
 565 570 575

Ala Ser Leu Leu Lys Val His Leu Gln Leu His Gly Phe Ser Val Phe
 580 585 590

Ile Asp Val Glu Lys Leu Glu Ala Gly Lys Phe Glu Asp Lys Leu Ile
 595 600 605

Gln Ser Val Ile Ala Ala Arg Asn Phe Val Leu Val Leu Ser Ala Gly
 610 615 620

Ala Leu Asp Lys Cys Met Gln Asp His Asp Cys Lys Asp Trp Val His
 625 630 635 640

Lys Glu Ile Val Thr Ala Leu Ser Cys Gly Lys Asn Ile Val Pro Ile
 645 650 655

Ile Asp Gly Phe Glu Trp Pro Glu Pro Gln Ala Leu Pro Glu Asp Met
 660 665 670

Gln Ala Val Leu Thr Phe Asn Gly Ile Lys Trp Ser His Glu Tyr Gln
 675 680 685

Glu Ala Thr Ile Glu Lys Ile Ile Arg Phe Leu Gln Gly Arg Pro Ser
 690 695 700

Gln Asp Ser Ser Ala Gly Ser Asp Thr Ser Leu Glu Gly Ala Thr Pro
 705 710 715 720

Met Gly Leu Pro

<210> SEQ ID NO 7
 <211> LENGTH: 42
 <212> TYPE: DNA
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: synthetically generated oligonucleotides

<400> SEQUENCE: 7
 atatatatgc ggccgcaaaa catgggcaat cgtttgagcg gc 42

<210> SEQ ID NO 8
 <211> LENGTH: 20
 <212> TYPE: DNA
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: synthetically generated oligonucleotides

<400> SEQUENCE: 8
 cgttagaacg cggctacaat 20

<210> SEQ ID NO 9
 <211> LENGTH: 127
 <212> TYPE: DNA
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:

-continued

```

<223> OTHER INFORMATION: synthetically generated oligonucleotides

<400> SEQUENCE: 9

agatactcga gttaccacaaa tatcatgcgc cggcattgg gggaggtggc cttggacaga      60
atgatgcccg aaagttcctc gtccctccatt tcgtgtttt ttatcagcga gcggaccttc    120
ttcatcg                                           127

<210> SEQ ID NO 10
<211> LENGTH: 36
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: synthetically generated oligonucleotides

<400> SEQUENCE: 10

gatcactagt ccaaaatc atgcgcccg cattgg                                           36

```

What is claimed is:

1. A method reducing axonal and/or synaptic degradation in a neuron, the method comprising:

selecting a neuron with or at risk for axonal and/or synaptic degradation; and

contacting the neuron with an effective amount of a composition that inhibits sterile α /Armadillo/Toll-Interleukin receptor homology domain protein (SARM) activity and/or expression for a time sufficient to inhibit SARM activity and/or expression, thereby reducing axonal and/or synaptic degradation in the neuron.

2. A method for reducing axonal and/or synaptic degradation in a subject with or at risk for developing axonal and/or synaptic degradation, the method comprising:

selecting a subject with or at risk for developing axonal and/or synaptic degradation; and

treating the subject with an effective amount of a composition that inhibits SARM activity and/or expression for a time sufficient to inhibit SARM activity and/or expression, thereby reducing axonal and/or synaptic degradation in the subject.

3. The method of claim **2**, wherein the subject has or is at risk of neurodegenerative disease.

4. The method of claim **2** or **3**, wherein the axonal and/or synaptic degradation is in the central nervous system (CNS) and/or the peripheral nervous system (PNS).

5. The method of claim **4**, wherein the axonal and/or synaptic degradation is in the PNS.

6. The method of claim **5**, wherein the subject has diabetes.

7. The method of claim **6**, wherein the subject has diabetic neuropathy.

8. The method of claim **5**, wherein the subject is scheduled to receive chemotherapy.

9. The method of claim **5**, wherein the subject is receiving chemotherapy or has received chemotherapy.

10. A method for identifying a compound that inhibits SARM activity and/or expression, the method comprising:

providing SARM;

contacting the SARM with a test compound; and

determining whether the test compound interacts with or binds to SARM, wherein a test compound that interacts or binds with SARM is a candidate compound that inhibits SARM activity and/or expression.

11. The method of claim **10**, wherein SARM and the test compound are contacted in silico.

12. The method of claim **10** or **11**, wherein SARM and the test compound are contacted in vitro.

13. The method of claim **10**, wherein determining whether the test compound interacts with or binds to SARM is performed directly.

14. The method of claim **10**, wherein determining whether the test compound interacts with or binds to SARM is performed indirectly.

15. A method for identifying a compound that inhibits SARM activity and/or expression, the method comprising:

providing a sample comprising SARM;

contacting the sample with a compound; and

measuring the transcriptional activity of SARM in the sample, wherein a decrease in the transcriptional activity of SARM in the sample in the presence of the compound indicates that the compound is a candidate compound that inhibits SARM activity and/or expression.

16. A method for identifying a compound that inhibits SARM activity and/or expression, the method comprising: contacting a neuron with the candidate compound of claim **10** or claim **15**;

axotomizing the neuron; and

determining whether axonal and/or synaptic degradation is altered in the presence of the candidate compound relative to axonal degradation in the absence of the compound, wherein a decrease in axonal and/or synaptic degradation indicates that the candidate compound is a compound that inhibits SARM activity and/or expression.

17. The method of claim **16**, further comprising:

obtaining the compound;

administering the compound to an animal model of neurodegenerative disease; and

assessing the degenerative disease in the animal in the presence of the compound, wherein a decrease in degenerative disease in the presence of the compound indicates that the compound inhibits SARM activity and/or expression.

* * * * *